

## Diverticular Disease

### NICE guideline: methods

*NICE guideline <number>*

*Methods*

*June 2019*

*Draft for Consultation*

*Developed by the National Guideline Centre,  
hosted by the Royal College of Physicians*



## **Disclaimer**

The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The recommendations in this guideline are not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and, where appropriate, their carer or guardian.

Local commissioners and providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties.

NICE guidelines cover health and care in England. Decisions on how they apply in other UK countries are made by ministers in the [Welsh Government](#), [Scottish Government](#), and [Northern Ireland Executive](#). All NICE guidance is subject to regular review and may be updated or withdrawn.

## **Copyright**

© NICE 2019. All rights reserved. Subject to [Notice of rights](#).

# Contents

<b>1</b>	<b>Development of the guideline</b> .....	<b>5</b>
1.1	What is a NICE guideline?.....	5
1.2	Remit.....	5
1.3	Who developed this guideline?.....	6
1.3.1	What this guideline covers .....	6
1.3.2	What this guideline does not cover.....	6
<b>2</b>	<b>Methods</b> .....	<b>7</b>
2.1	Developing the review questions and outcomes.....	7
2.2	Searching for evidence.....	14
2.2.1	Clinical and health economics literature searches.....	14
2.3	Identifying and analysing evidence of effectiveness .....	15
2.3.1	Inclusion and exclusion criteria .....	16
2.3.2	Type of studies.....	16
2.3.3	Methods of combining clinical studies .....	17
2.3.4	Appraising the quality of evidence by outcomes.....	20
2.3.5	Assessing clinical importance .....	29
2.3.6	Clinical evidence statements.....	29
2.4	Identifying and analysing evidence of cost effectiveness .....	30
2.4.1	Literature review .....	30
2.4.2	Undertaking new health economic analysis.....	32
2.4.3	Cost-effectiveness criteria .....	32
2.4.4	In the absence of health economic evidence.....	33
2.5	Formal consensus methods .....	33
2.5.1	Introduction .....	33
2.5.2	Modified Delphi methodology .....	33
2.5.3	Qualitative analysis .....	34
2.6	Developing recommendations .....	34
2.6.1	Research recommendations .....	36
2.6.2	Validation process.....	36
2.6.3	Updating the guideline .....	36
2.6.4	Disclaimer .....	36
2.6.5	Funding.....	36
<b>3</b>	<b>Acronyms and abbreviations</b> .....	<b>37</b>
<b>4</b>	<b>Glossary</b> .....	<b>38</b>
4.1	Guideline-specific terms .....	38
4.2	General terms .....	40
<b>5</b>	<b>Appendix 1</b> .....	<b>52</b>

# 1 Development of the guideline

## 1.1 What is a NICE guideline?

NICE guidelines are recommendations for the care of individuals in specific clinical conditions or circumstances within the NHS – from prevention and self-care through primary and secondary care to more specialised services. These may also include elements of social care or public health measures. We base our guidelines on the best available research evidence, with the aim of improving the quality of healthcare. We use predetermined and systematic methods to identify and evaluate the evidence relating to specific review questions.

NICE guidelines can:

- provide recommendations for the treatment and care of people by health professionals
- be used to develop standards to assess the clinical practice of individual health professionals
- be used in the education and training of health professionals
- help patients to make informed decisions
- improve communication between patient and health professional.

While guidelines assist the practice of healthcare professionals, they do not replace their knowledge and skills.

We produce our guidelines using the following steps:

- A guideline topic is referred to NICE from NHS England.
- Stakeholders register an interest in the guideline and are consulted throughout the development process.
- The scope is prepared by the National Guideline Centre (NGC).
- The NGC establishes a guideline committee.
- A draft guideline is produced after the group assesses the available evidence and makes recommendations.
- There is a consultation on the draft guideline.
- The final guideline is produced.

The guideline is made up of a collection of documents including this Methods report and a number of evidence reports covering each of the review questions included in the guideline. These can all be downloaded from NICE at [www.nice.org.uk](http://www.nice.org.uk).

NICE also publishes a summary of the recommendation in this guideline, known as ‘the NICE guideline’.

NICE Pathways brings together all connected NICE guidance.

## 1.2 Remit

NICE received the remit for this guideline from NHS England. NICE commissioned the NGC to produce the guideline.

The remit for this guideline is:

Diverticular disease

## 1.3 Who developed this guideline?

A multidisciplinary guideline committee comprising health professionals and researchers as well as lay members developed this guideline (see the list of guideline committee members and the acknowledgements).

The National Institute for Health and Care Excellence (NICE) funds the National Guideline Centre (NGC) and thus supported the development of this guideline. The committee was convened by the NGC and chaired by Jamie Dalrymple in accordance with guidance from NICE.

The group met approximately every 6 weeks during the development of the guideline. At the start of the guideline development process all committee members declared interests including consultancies, fee-paid work, shareholdings, fellowships and support from the healthcare industry. At all subsequent committee meetings, members declared arising conflicts of interest.

Members were either required to withdraw completely or for part of the discussion if their declared interest made it appropriate. The details of declared interests and the actions taken are shown in the declaration of interest register for this guideline published on the NICE website.

Staff from the NGC provided methodological support and guidance for the development process. The team working on the guideline included a project manager, systematic reviewers (research fellows), health economists and information specialists. They undertook systematic searches of the literature, appraised the evidence, conducted meta-analysis and cost-effectiveness analysis where appropriate and drafted the guideline in collaboration with the committee.

### 1.3.1 What this guideline covers

The populations covered by this guideline are people aged 18 years and over with;

- diverticulosis,
- suspected or confirmed diverticular disease
- suspected or confirmed diverticulitis.

The key areas clinical areas covered by this guideline are the;

- management of diverticulosis,
- diagnosis and management of diverticular disease
- diagnosis and management of acute diverticulitis
- information and support needs of people with diverticulosis, diverticular disease and diverticulitis, their families and carers.

For further details please refer to the scope for this guideline (published on the NICE website) and the review questions in section 2.1.

### 1.3.2 What this guideline does not cover

This guideline will not cover children and young people aged 17 years and younger.

## 2 Methods

This report sets out in detail the methods used to review the evidence and to develop the recommendations that are presented in each of the evidence reviews for this guideline. This guidance was developed in accordance with the methods outlined in the NICE guidelines manual, 2014 version.<sup>4</sup>

Sections 2.1 to 2.3 describe the process used to identify and review clinical evidence (summarised in Figure 1), sections 2.2 and 2.4 describe the process used to identify and review the health economic evidence, and section 2.5 describes the process used to develop recommendations.

**Figure 1: Step-by-step process of review of evidence in the guideline**



### 2.1 Developing the review questions and outcomes

Review questions were developed using a PICO framework (population, intervention, comparison and outcome) for intervention reviews; using a framework of population, index tests, reference standard and target condition for reviews of diagnostic test accuracy; using population, presence or absence of factors under investigation (for example prognostic factors) and outcomes for prognostic reviews; and using a framework of population, setting and context for qualitative reviews.

This use of a framework guided the literature searching process, critical appraisal and synthesis of evidence, and facilitated the development of recommendations by the guideline committee. The review questions were drafted by the NGC technical team and refined and

1 validated by the committee. The questions were based on the key clinical areas identified in  
2 the scope.

3 A total of 19 review questions were identified.

4 Full literature searches, critical appraisals and evidence reviews were completed for all the  
5 specified review questions.

6 **Table 1: Review questions**

Evidence report	Type of review	Review questions	Outcomes
1	Intervention	What is the most clinically and cost-effective management strategy for the prevention of diverticular disease in patients with diverticulosis?	<p>Critical outcomes:</p> <ul style="list-style-type: none"> <li>• Progression of disease: <ul style="list-style-type: none"> <li>○ Symptomatic diverticular disease</li> <li>○ Acute diverticulitis</li> <li>○ Complications (infections, abscesses, perforation, stricture, fistula)</li> </ul> </li> <li>• Quality of life</li> </ul> <p>Important outcomes:</p> <ul style="list-style-type: none"> <li>• Side effects of <ul style="list-style-type: none"> <li>○ probiotics and laxatives: diarrhoea, bloating, abdominal pain</li> </ul> </li> <li>• Mortality</li> </ul>
2.1	Diagnostic/prognostic	What symptoms and signs indicate diverticular disease as a possible diagnosis?	<ul style="list-style-type: none"> <li>• Sensitivity</li> <li>• Specificity</li> <li>• Positive Predictive Value (PPV)</li> <li>• Negative Predictive Value (NPV)</li> <li>• Receiver Operating Characteristic (ROC) curve or area under curve</li> <li>• Relative risk (RR)</li> <li>• Diagnosis of Diverticular disease</li> </ul>
2.2	Diagnostic/prognostic	In which people with suspected diverticular disease should investigations be performed?	<ul style="list-style-type: none"> <li>• Sensitivity</li> <li>• Specificity</li> <li>• Positive Predictive Value (PPV)</li> <li>• Negative Predictive Value (NPV)</li> <li>• Receiver Operating Characteristic (ROC) curve or area under curve</li> <li>• Relative risk (RR)</li> <li>• Diagnosis of Diverticular disease</li> <li>• Diagnosis of Diverticulitis</li> </ul>
2.3	Diagnostic	What is the diagnostic accuracy and cost effectiveness of tests to	<ul style="list-style-type: none"> <li>• Sensitivity</li> </ul>

Evidence report	Type of review	Review questions	Outcomes
		diagnose diverticular disease?	<ul style="list-style-type: none"> <li>• Specificity</li> <li>• Positive Predictive Value (PPV)</li> <li>• Negative Predictive Value (NPV)</li> <li>• Receiver Operating Characteristic (ROC) curve or area under curve</li> </ul>
2.4	Intervention	What is the most clinically and cost-effective treatment for diverticular disease?	<ul style="list-style-type: none"> <li>• Progression of disease               <ul style="list-style-type: none"> <li>○ Acute diverticulitis</li> <li>○ Hospitalisation</li> <li>○ Need for surgery</li> <li>○ Complications (infections, abscesses, perforation)</li> </ul> </li> <li>• Symptom control (pain relief, bowel habit)</li> <li>• Quality of life</li> </ul> <p>Important outcomes:</p> <ul style="list-style-type: none"> <li>• Mortality</li> <li>• Side effects of:               <ul style="list-style-type: none"> <li>○ Antibiotics: nausea and vomiting, diarrhoea, infections related to antibiotics</li> <li>○ Analgesics: nausea and vomiting, constipation</li> </ul> </li> <li>• Antispasmodics: AF</li> </ul>
2.5	Intervention	What is the most clinically and cost effective management strategy for people with recurrent episodes of diverticular disease (including indications for elective surgery/surgical opinion)?	<p>Critical outcomes:</p> <ul style="list-style-type: none"> <li>• Quality of life</li> <li>• Mortality</li> <li>• Morbidity</li> <li>• Progression of disease to acute diverticulitis (diagnosis)</li> <li>• Complications               <ul style="list-style-type: none"> <li>○ infections</li> <li>○ abscesses</li> <li>○ perforation</li> <li>○ fistula</li> <li>○ stricture</li> </ul> </li> </ul> <p>Important outcomes:</p> <ul style="list-style-type: none"> <li>• Side effects of medications</li> <li>• Pain/symptom control</li> <li>• Hospitalisation</li> <li>• Recurrence of symptoms</li> </ul>
3.1	Prognostic	In adults with suspected acute diverticulitis, what are the referral criteria for urgent hospital assessment?	<ul style="list-style-type: none"> <li>• Hospital admission</li> <li>• Discharge from A&amp;E</li> <li>• Urgent outpatient appointment/ surgical triage</li> </ul>

Evidence report	Type of review	Review questions	Outcomes
			<ul style="list-style-type: none"> <li>• Acute diverticulitis</li> <li>• Development of complications (fistula, perforation, abscess, stricture)</li> </ul>
3.2	Diagnostic	For people with suspected acute diverticulitis who are not referred for urgent hospital assessment, which investigations are clinically and cost effective (for example full blood count, CRP, endoscopy, CT and MRI) in the diagnosis and assessment of acute diverticulitis during and after the acute episode?	<ul style="list-style-type: none"> <li>• Sensitivity</li> <li>• Specificity</li> <li>• Positive Predictive Value (PPV)</li> <li>• Negative Predictive Value (NPV)</li> <li>• Receiver Operating Characteristic (ROC) curve or area under curve</li> <li>• Relative risk (RR)</li> </ul>
3.3	Diagnostic	For people with suspected acute diverticulitis who are referred for urgent hospital assessment, which investigations are clinically and cost effective (for example full blood count, CRP, endoscopy, CT and MRI) in the diagnosis and assessment of acute diverticulitis during and after the acute episode?	<ul style="list-style-type: none"> <li>• Sensitivity</li> <li>• Specificity</li> <li>• Positive Predictive Value (PPV)</li> <li>• Negative Predictive Value (NPV)</li> <li>• Receiver Operating Characteristic (ROC) curve or area under curve</li> <li>• Relative risk (RR)</li> </ul>
3.4	Intervention	What is the most clinically and cost-effective non-surgical treatments for acute diverticulitis?	<p>Critical outcomes:</p> <ul style="list-style-type: none"> <li>• Progression of disease</li> <li>• Hospitalisation</li> <li>• Need for surgery</li> <li>• Complications (infections, abscesses, perforation)</li> <li>• Recurrence rates of acute diverticulitis (minimum 1year)</li> <li>• Quality of life</li> </ul> <p>Important outcomes:</p> <ul style="list-style-type: none"> <li>• Mortality</li> <li>• Symptom control (pain relief)</li> <li>• Side effects of <ul style="list-style-type: none"> <li>○ Antibiotics: nausea and vomiting, diarrhoea, infections related to antibiotics</li> <li>○ Analgesics: nausea and vomiting, constipation</li> </ul> </li> </ul>

Evidence report	Type of review	Review questions	Outcomes
3.5	Prognostic	What are the indications for surgery in people with acute diverticulitis?	<p>Critical outcomes:</p> <ul style="list-style-type: none"> <li>• Mortality</li> <li>• morbidity</li> <li>• Recurrence rates of acute diverticulitis</li> <li>• Hospitalisation</li> <li>• Need for surgery</li> <li>• Progression of disease/ complications: <ul style="list-style-type: none"> <li>○ Infections</li> <li>○ Abscesses</li> <li>○ Perforation</li> <li>○ Stricture</li> <li>○ Fistula</li> </ul> </li> </ul>
3.6.1	Intervention	What is the most appropriate time for surgery in people with complicated acute diverticulitis?	<p>Critical outcomes:</p> <ul style="list-style-type: none"> <li>• Quality of life</li> <li>• Mortality</li> <li>• Morbidity</li> <li>• Progression of disease</li> <li>• Complications: <ul style="list-style-type: none"> <li>○ infections</li> <li>○ abscesses</li> <li>○ perforation</li> <li>○ fistula</li> <li>○ stricture</li> </ul> </li> <li>• Recurrence rates of acute diverticulitis</li> <li>• Hospitalisation</li> <li>• Need for further surgery</li> </ul> <p>Important outcomes:</p> <ul style="list-style-type: none"> <li>• Symptom control/recurrence, for example pain relief, bowel habit</li> </ul>
3.6.2	Intervention	What is the most appropriate method of resection in people with acute diverticulitis?	<p>Critical outcomes:</p> <ul style="list-style-type: none"> <li>• Quality of life</li> <li>• Mortality</li> <li>• Morbidity</li> <li>• Progression of disease</li> <li>• Complications: <ul style="list-style-type: none"> <li>○ infections</li> <li>○ abscesses</li> <li>○ perforation</li> <li>○ fistula</li> <li>○ stricture</li> </ul> </li> <li>• Recurrence rates of acute diverticulitis</li> </ul>

Evidence report	Type of review	Review questions	Outcomes
			<ul style="list-style-type: none"> <li>• Hospitalisation</li> <li>• Need for further surgery</li> <li>• Anastomotic leak</li> </ul> <p>Important outcomes:</p> <ul style="list-style-type: none"> <li>• Symptom control/recurrence, for example pain relief, bowel habit</li> </ul>
3.6.3	Intervention	What is the most appropriate extent of colectomy in people with complicated acute diverticulitis?	<p>Critical outcomes:</p> <ul style="list-style-type: none"> <li>• Quality of life</li> <li>• Mortality</li> <li>• Morbidity</li> <li>• Progression of disease</li> <li>• Complications: <ul style="list-style-type: none"> <li>○ infections</li> <li>○ abscesses</li> <li>○ perforation</li> <li>○ fistula</li> <li>○ stricture</li> </ul> </li> <li>• Recurrence rates of acute diverticulitis</li> <li>• Hospitalisation</li> <li>• Need for further surgery</li> <li>• Anastomotic leak</li> </ul> <p>Important outcomes:</p> <ul style="list-style-type: none"> <li>• Symptom control/recurrence, for example pain relief, bowel habit</li> </ul>
3.6.4	Intervention	What is the most appropriate time of anastomosis in people with complicated acute diverticulitis?	<p>Critical outcomes:</p> <ul style="list-style-type: none"> <li>• Quality of life</li> <li>• Mortality</li> <li>• Morbidity</li> <li>• Progression of disease</li> <li>• Complications: <ul style="list-style-type: none"> <li>○ infections</li> <li>○ abscesses</li> <li>○ perforation</li> <li>○ fistula</li> <li>○ stricture</li> </ul> </li> <li>• Recurrence rates of acute diverticulitis</li> <li>• Hospitalisation</li> <li>• Need for further surgery</li> <li>• Anastomotic leak</li> <li>• Stoma complications</li> </ul> <p>Important outcomes:</p> <ul style="list-style-type: none"> <li>• Symptom control/recurrence,</li> </ul>

Evidence report	Type of review	Review questions	Outcomes
			for example pain relief, bowel habit
3.7	Intervention	What is the most clinical and cost effective treatment for the management of abscesses?	<p>Critical outcomes:</p> <ul style="list-style-type: none"> <li>• Quality of life</li> <li>• Mortality</li> <li>• Morbidity</li> <li>• Progression of disease</li> <li>• recurrence of abscess</li> <li>• Complications: <ul style="list-style-type: none"> <li>○ infections</li> <li>○ abscesses</li> <li>○ perforation</li> <li>○ fistula</li> <li>○ stricture</li> <li>○ haemorrhage</li> </ul> </li> <li>• Re-hospitalisation</li> <li>• Need for further surgery/percutaneous drain</li> <li>• Anastomotic leak rate</li> <li>• Stoma</li> </ul> <p>Important outcomes:</p> <ul style="list-style-type: none"> <li>• complications of percutaneous drainage</li> </ul>
3.8	intervention	What is the clinical and cost effectiveness of laparoscopic lavage versus resectional surgery for the management of bowel perforations?	<p>Critical outcomes:</p> <ul style="list-style-type: none"> <li>• Quality of life</li> <li>• Mortality</li> <li>• Morbidity</li> <li>• Progression of disease</li> <li>• Complications: <ul style="list-style-type: none"> <li>○ infections</li> <li>○ abscesses</li> <li>○ perforation</li> <li>○ fistula</li> <li>○ stricture</li> <li>○ haemorrhage</li> </ul> </li> <li>• Re-hospitalisation</li> <li>• Need for further surgery/percutaneous drain</li> <li>• Anastomotic leak rate</li> <li>• Stoma formation</li> </ul>
3.9	Intervention	What is the most clinically and cost effective management strategy for people with recurrent episodes of acute diverticulitis?	<p>Critical outcomes:</p> <ul style="list-style-type: none"> <li>• Quality of life</li> <li>• Mortality</li> <li>• Complications:</li> </ul>

Evidence report	Type of review	Review questions	Outcomes
			<ul style="list-style-type: none"> <li>• infections</li> <li>• abscesses</li> <li>• perforation</li> <li>• fistula</li> <li>• stricture</li> <li>• Recurrence rates of acute diverticulitis</li> <li>• Hospitalisation related to diverticular disease</li> <li>• Need for surgery for diverticular disease</li> </ul> <p>Important outcomes:</p> <ul style="list-style-type: none"> <li>• Symptom control: pain relief, bloating, night sweats, fever</li> <li>• Side effects of: <ul style="list-style-type: none"> <li>○ antibiotics, nausea and vomiting, antibiotics-related infection</li> <li>○ analgesics, constipation, nausea and vomiting</li> <li>○ surgery, morbidity and mortality</li> </ul> </li> </ul>
4.1	Qualitative	What information and support do people with diverticulosis, diverticular disease, and diverticulitis, and their families and carers, need?	<p>Themes will be derived from the evidence identified for this review and not pre-specified. However for information to guide the technical team, relevant themes may include:</p> <ul style="list-style-type: none"> <li>• Decision making</li> <li>• Preferred format of information provision</li> <li>• Content of information</li> <li>• Impact of treatment on lifestyle</li> <li>• Information sources other than healthcare professionals (e.g. support groups, online resources)</li> <li>• Psychological support</li> <li>• Delivery of support (e.g. nurse, dietician, peer groups)</li> </ul>

## 1 2.2 Searching for evidence

### 2 2.2.1 Clinical and health economics literature searches

3 Systematic literature searches were undertaken to identify all published clinical and health  
4 economic evidence relevant to the review questions. Searches were undertaken according to  
5 the parameters stipulated within the NICE guidelines manual 2014 (see

1 <https://www.nice.org.uk/process/pmg20/>). Databases were searched using relevant medical  
2 subject headings, free-text terms and study-type filters where appropriate. Where possible,  
3 searches were restricted to papers published in English. Studies published in languages  
4 other than English were not reviewed. All searches were updated on 13 November 2018.  
5 Papers published or added to databases after this date were not considered. If new  
6 evidence, falling outside of the timeframe for the guideline searches, is identified, for  
7 example in consultation comments received from stakeholders, the impact on the guideline  
8 will be considered, and any further action agreed between NGC and NICE staff with a quality  
9 assurance role.

10 Prior to running, search strategies were quality assured using a variety of approaches.  
11 Medline search strategies were checked by a second information specialist before being run.  
12 Searches were cross-checked with reference lists of highly relevant papers, searches in  
13 other systematic reviews were analysed, and committee members were requested to  
14 highlight additional studies.

15 During the scoping stage, a search was conducted for guidelines and reports on the websites  
16 including:

- 17 • Guidelines International Network database ([www.g-i-n.net](http://www.g-i-n.net))
- 18 • National Institute for Health and Care Excellence (NICE) ([www.nice.org.uk](http://www.nice.org.uk))
- 19 • NHS Evidence Search ([www.evidence.nhs.uk](http://www.evidence.nhs.uk))

20 Searching for unpublished literature was not undertaken. The NGC and NICE do not have  
21 access to drug manufacturers' unpublished clinical trial results, so the clinical evidence  
22 considered by the committee for pharmaceutical interventions may be different from that  
23 considered by the MHRA and European Medicines Agency for the purposes of licensing and  
24 safety regulation.

25 Detailed search strategies can be found as an appendix to each evidence review.

## 26 **2.3 Identifying and analysing evidence of effectiveness**

27 Research fellows conducted the tasks listed below, which are described in further detail in  
28 the rest of this section:

- 29 • Identified potentially relevant studies for each review question from the relevant search  
30 results by reviewing titles and abstracts. Full papers were then obtained.
- 31 • Reviewed full papers against pre specified inclusion and exclusion criteria to identify  
32 studies that addressed the review question in the appropriate population, and reported on  
33 outcomes of interest (review protocols are included in an appendix to each of the  
34 evidence reports).
- 35 • Critically appraised relevant studies using the appropriate study design checklist as  
36 specified in the NICE guidelines manual (Appendix H of the NICE methods manual).<sup>4</sup>  
37 Prognostic studies were critically appraised using the QUIPS checklist. Qualitative studies  
38 were critically appraised using the GRADE CERQual approach for rating confidence in the  
39 body of evidence as a whole and using an NGC checklist for the methodological  
40 limitations section of the quality assessment.
- 41 • Extracted key information about interventional study methods and results using 'Evidbase',  
42 NGC's purpose-built software. Evidbase produces summary evidence tables, including  
43 critical appraisal ratings. Key information about non-interventional study methods and  
44 results was manually extracted onto standard evidence tables and critically appraised  
45 separately (evidence tables are included in an appendix to each of the evidence reports).
- 46 • Generated summaries of the evidence by outcome. Outcome data were combined,  
47 analysed and reported according to study design:

- 1           ○ Randomised data were meta-analysed where appropriate and reported in GRADE
- 2           profile tables.
- 3           ○ Data from non-randomised studies were presented as a range of values in GRADE
- 4           profile tables or meta-analysed if appropriate.
- 5           ○ Prognostic data were meta-analysed where appropriate and reported in GRADE profile
- 6           tables.
- 7           ○ Diagnostic data studies were meta-analysed where appropriate or presented as a
- 8           range of values in adapted GRADE profile tables
- 9           ○ Qualitative data were synthesised across studies and presented as summary
- 10          statements with accompanying GRADE CERQual ratings for each review finding.
- 11          ● A sample of a minimum of 10% of the abstract lists of the first 3 sifts by new reviewers
- 12          and those for complex review questions (for example, prognostic reviews) were double-
- 13          sifted by a senior research fellow and any discrepancies were rectified. All of the evidence
- 14          reviews were quality assured by a senior research fellow. This included checking:
- 15               ○ papers were included or excluded appropriately
- 16               ○ a sample of the data extractions
- 17               ○ correct methods were used to synthesise data
- 18               ○ a sample of the risk of bias assessments.

### 19 **2.3.1 Inclusion and exclusion criteria**

20           The inclusion and exclusion of studies was based on the criteria defined in the review  
21           protocols, which can be found in an appendix to each of the evidence reports. Excluded  
22           studies (with the reasons for their exclusion) are listed in another appendix to each of the  
23           evidence reports. The committee was consulted about any uncertainty regarding inclusion or  
24           exclusion.

25           The key population inclusion criterion was:

- 26               ● People aged 18 years and above with diverticulosis, diverticular disease or
- 27               diverticulitis.

28           The key population exclusion criterion was:

- 29               ● People below the age of 18 years.

31           Conference abstracts were not automatically excluded from any review. The abstracts were  
32           initially assessed against the inclusion criteria for the review question and further processed  
33           when a full publication was not available for that review question. If the abstracts were  
34           included the authors were contacted for further information. No relevant conference abstracts  
35           were identified for this guideline. Literature reviews, posters, letters, editorials, comment  
36           articles, unpublished studies and studies not in English were excluded.

### 37 **2.3.2 Type of studies**

38           Randomised trials, non-randomised intervention studies, and other observational studies  
39           (including diagnostic or prognostic studies) were included in the evidence reviews as  
40           appropriate.

41           For most intervention reviews in this guideline, parallel randomised controlled trials (RCTs)  
42           were included because they are considered the most robust type of study design that can  
43           produce an unbiased estimate of the intervention effects. Crossover RCTs were not  
44           appropriate for the intervention reviews as the guideline committee were interested in  
45           assessing the outcome effects on people having undergone distinct interventions. If non-  
46           randomised intervention studies were considered appropriate for inclusion (for example,

1 where no randomised evidence was available for critical outcomes) the committee stated a  
2 priori in the protocol that either certain identified variables must be equivalent at baseline or  
3 else the analysis had to adjust for any baseline differences. If the study did not fulfil either  
4 criterion it was excluded. Please refer to the review protocols in each evidence report for full  
5 details on the study design of studies selected for each review question.

6 For diagnostic review questions, diagnostic RCTs, cross-sectional studies and retrospective  
7 studies were included. For prognostic review questions, prospective and retrospective cohort  
8 studies were included. Case-control studies were not included.

9 Where data from non-randomised studies were included, the results for each outcome were  
10 presented separately for each study or meta-analysed if appropriate.

### 11 **2.3.3 Methods of combining clinical studies**

#### 12 **2.3.3.1 Data synthesis for intervention reviews**

13 Where possible, meta-analyses were conducted using Cochrane Review Manager  
14 (RevMan5)<sup>8</sup> software to combine the data given in all studies for each of the outcomes of  
15 interest for the review question.

16 For some questions stratification was used, and this is documented in the individual review  
17 question protocols in each evidence report.

##### 18 **2.3.3.1.1 Analysis of different types of data**

#### 19 **Dichotomous outcomes**

20 Fixed-effects (Mantel-Haenszel) techniques (using an inverse variance method for pooling)  
21 were used to calculate risk ratios (relative risk, RR) for the binary outcomes, which included:

- 22 • mortality
- 23 • complications
- 24 • recurrence rates
- 25 • rehospitalisation
- 26 • adverse events

27 The absolute risk difference was also calculated using GRADEpro<sup>3</sup> software, using the  
28 median event rate in the control arm of the pooled results.

29 For binary variables where there were zero events in either arm or a less than 1% event rate,  
30 Peto odds ratios, rather than risk ratios, were calculated. Peto odds ratios are more  
31 appropriate for data with a low number of events.

32 Where sufficient information was provided, hazard ratios were calculated in preference for  
33 outcomes such as mortality where the time to the event occurring was important for decision-  
34 making.

#### 35 **Continuous outcomes**

36 Continuous outcomes were analysed using an inverse variance method for pooling weighted  
37 mean differences. These outcomes included:

- 38 • quality of life measures
- 39 • symptom scores
- 40 • pain scores

1 The means and standard deviations of continuous outcomes are required for meta-analysis.  
2 However, in cases where standard deviations were not reported, the standard error was  
3 calculated if the p values or 95% confidence intervals (95% CI) were reported, and meta-  
4 analysis was undertaken with the mean and standard error using the generic inverse  
5 variance method in Cochrane Review Manager (RevMan5<sup>8</sup> software).

#### 62.3.3.1.2 **Generic inverse variance**

7 If a study reported only the summary statistic and 95% CI the generic-inverse variance  
8 method was used to enter data into RevMan5.<sup>8</sup> If the control event rate was reported this  
9 was used to generate the absolute risk difference in GRADEpro.<sup>3</sup> If multivariate analysis was  
10 used to derive the summary statistic but no adjusted control event rate was reported no  
11 absolute risk difference was calculated.

#### 122.3.3.1.3 **Heterogeneity**

13 Statistical heterogeneity was assessed for each meta-analysis estimate by considering the  
14 chi-squared test for significance at  $p < 0.1$  or an I-squared ( $I^2$ ) inconsistency statistic (with an I-  
15 squared value of more than 50% indicating significant heterogeneity) as well as the  
16 distribution of effects. Where significant heterogeneity was present, based on the protocol,  
17 predefined subgrouping of studies was carried out for either:

- 18 • people of Asian family origin as they are known to develop right-sided diverticula
- 19 • transplant patients/ immunocompromised
- 20 • age (<50 years and ≥50 years)

21  
22 If the subgroup analysis resolved heterogeneity within all of the derived subgroups, then  
23 each of the derived subgroups were adopted as separate outcomes (providing at least 1  
24 study remained in each subgroup. For example, instead of the single outcome of 'mortality',  
25 this was separated into 2 outcomes '*mortality in people aged under 50*' and '*missed*  
26 *diagnosis in people aged 50 and over*'. Assessments of potential differences in effect  
27 between subgroups were based on the chi-squared tests for heterogeneity statistics between  
28 subgroups. Any subgroup differences were interpreted with caution as separating the groups  
29 breaks the study randomisation and as such is subject to uncontrolled confounding.

30 If all predefined strategies of subgrouping were unable to explain statistical heterogeneity  
31 within each derived subgroup, then a random effects (DerSimonian and Laird) model was  
32 employed to the entire group of studies in the meta-analysis. A random-effects model  
33 assumes a distribution of populations, rather than a single population. This leads to a  
34 widening of the confidence interval around the overall estimate, thus providing a more  
35 realistic interpretation of the true distribution of effects across more than 1 population. If,  
36 however, the committee considered the heterogeneity was so large that meta-analysis was  
37 inappropriate, then the results were described narratively.

#### 38 **2.3.3.2 Data synthesis for prognostic factor reviews**

39 Odds ratios (ORs), with their 95% CIs, for the effect of the pre specified prognostic factors  
40 were extracted from the studies. Studies were only included if the confounders pre specified  
41 by the committee were either matched at baseline or were adjusted for in multivariate  
42 analysis.

43 Studies of lower risk of bias were preferred, taking into account the analysis and the study  
44 design. In particular, prospective cohort studies were preferred if they reported multivariable  
45 analyses that adjusted for key confounders identified by the committee at the protocol stage  
46 for that outcome.

### 1 2.3.3.3 Data synthesis for diagnostic test accuracy reviews

2 Two separate review protocols were produced to reflect the 2 different diagnostic study  
3 designs, i.e. test and treat protocol and diagnostic test accuracy protocol.

#### 42.3.3.3.1 Diagnostic RCTs

5 Diagnostic RCTs (sometimes referred to as test and treat trials) are a randomised  
6 comparison of 2 diagnostic tests, with study outcomes being clinically important  
7 consequences of the diagnosis (patient-related outcome measures similar to those in  
8 intervention trials, such as mortality). Patients are randomised to receive test A or test B,  
9 followed by identical therapeutic interventions based on the results of the test (so someone  
10 with a positive result would receive the same treatment regardless of whether they were  
11 diagnosed by test A or test B). Downstream patient outcomes are then compared between  
12 the 2 groups. As treatment is the same in both arms of the trial, any differences in patient  
13 outcomes will reflect the accuracy of the tests in correctly establishing who does and does  
14 not have the condition. Data were synthesised using the same methods for intervention  
15 reviews (see section 2.3.3.1.1 above).

#### 162.3.3.3.2 Diagnostic accuracy studies

17 For diagnostic test accuracy studies, a positive result on the index test was found if the  
18 patient had values of the measured quantity above or below a threshold value, and different  
19 thresholds could be used. The thresholds were pre specified by the committee including  
20 whether or not data could be pooled across a range of thresholds. Diagnostic test accuracy  
21 measures used in the analysis were: area under the receiver operating characteristics (ROC)  
22 curve (AUC), and, for different thresholds (if appropriate), sensitivity and specificity. The  
23 threshold of a diagnostic test is defined as the value at which the test can best differentiate  
24 between those with and without the target condition. In practice this varies amongst studies.  
25 If a test has a high sensitivity then very few people with the condition will be missed (few  
26 false negatives). For example, a test with a sensitivity of 97% will only miss 3% of people  
27 with the condition. Conversely, if a test has a high specificity then few people without the  
28 condition would be incorrectly diagnosed (few false positives). For example, a test with a  
29 specificity of 97% will only incorrectly diagnose 3% of people who do not have the condition  
30 as positive. For this guideline, sensitivity was considered more important than specificity due  
31 to the consequences of a missed diagnosis (false negative result). Coupled forest plots of  
32 sensitivity and specificity with their 95% CIs across studies (at various thresholds) were  
33 produced for each test, using RevMan5.<sup>8</sup> In order to do this, 2x2 tables (the number of true  
34 positives, false positives, true negatives and false negatives) were directly taken from the  
35 study if given, or else were derived from raw data or calculated from the set of test accuracy  
36 statistics.

37 If appropriate, to allow comparison between tests, summary published ROC curves were  
38 incorporated into the review. A ROC plot shows true positive rate (sensitivity) as a function of  
39 false positive rate (1 minus specificity).

40 Heterogeneity or inconsistency amongst studies was visually inspected in the forest plots  
41 and pooled diagnostic meta-analysis plots.

42 Area under the ROC curve (AUC) data for each study were also plotted on a graph, for each  
43 diagnostic test. The AUC describes the overall diagnostic accuracy across the full range of  
44 thresholds. The following criteria were used for evaluating AUCs:

- 45 •  $\leq 0.50$ : worse than chance
- 46 • 0.50–0.60: very poor
- 47 • 0.61–0.70: poor
- 48 • 0.71–0.80: moderate
- 49 • 0.81–0.92: good

- 1 • 0.91–1.00: excellent or perfect test.

2 Heterogeneity or inconsistency amongst studies was visually inspected.

### 3 2.3.3.4 Data synthesis for qualitative study reviews

4 The main findings for each included paper were identified and thematic analysis methods  
5 were used to synthesise this information into broad overarching themes which were  
6 summarised into the main review findings. The evidence was presented in the form of a  
7 narrative summary detailing the evidence from the relevant papers and how this informed the  
8 overall review finding plus a statement on the level of confidence for that review finding.  
9 Considerable limitations and issues around relevance were listed. A summary evidence table  
10 with the succinct summary statements for each review finding was produced including the  
11 associated quality assessment.

## 12 2.3.4 Appraising the quality of evidence by outcomes

### 13 2.3.4.1 Intervention reviews

14 The evidence for outcomes from the included RCTs and, where appropriate, non-randomised  
15 intervention studies, were evaluated and presented using an adaptation of the ‘Grading of  
16 Recommendations Assessment, Development and Evaluation (GRADE) toolbox’ developed  
17 by the international GRADE working group (<http://www.gradeworkinggroup.org/>). The  
18 software (GRADEpro<sup>3</sup>) developed by the GRADE working group was used to assess the  
19 quality of each outcome, taking into account individual study quality and the meta-analysis  
20 results.

21 Each outcome was first examined for each of the quality elements listed and defined in Table  
22 2.

23 **Table 2: Description of quality elements in GRADE for intervention studies**

Quality element	Description
Risk of bias	Limitations in the study design and implementation may bias the estimates of the treatment effect. Major limitations in studies decrease the confidence in the estimate of the effect. Examples of such limitations are selection bias (often due to poor allocation concealment), performance and detection bias (often due to a lack of blinding of the patient, healthcare professional or assessor) and attrition bias (due to missing data causing systematic bias in the analysis).
Indirectness	Indirectness refers to differences in study population, intervention, comparator and outcomes between the available evidence and the review question.
Inconsistency	Inconsistency refers to an unexplained heterogeneity of effect estimates between studies in the same meta-analysis.
Imprecision	Results are imprecise when studies include relatively few patients and few events (or highly variable measures) and thus have wide confidence intervals around the estimate of the effect relative to clinically important thresholds. 95% confidence intervals denote the possible range of locations of the true population effect at a 95% probability, and so wide confidence intervals may denote a result that is consistent with conflicting interpretations (for example a result may be consistent with both clinical benefit AND clinical harm) and thus be imprecise.
Publication bias	Publication bias is a systematic underestimate or overestimate of the underlying beneficial or harmful effect due to the selective publication of studies. A closely related phenomenon is where some papers fail to report an outcome that is inconclusive, thus leading to an overestimate of the effectiveness of that outcome.
Other issues	Sometimes randomisation may not adequately lead to group equivalence of confounders, and if so this may lead to bias, which should be taken into account.

Quality element	Description
	Potential conflicts of interest, often caused by excessive pharmaceutical company involvement in the publication of a study, should also be noted.

1 Details of how the 4 main quality elements (risk of bias, indirectness, inconsistency and  
2 imprecision) were appraised for each outcome are given below. Publication or other bias was  
3 only taken into consideration in the quality assessment if it was apparent.

#### 42.3.4.1.1 *Risk of bias*

5 The main domains of bias for RCTs are listed in Table 3. Each outcome had its risk of bias  
6 assessed within each study first. For each study, if there were no risks of bias in any domain,  
7 the risk of bias was given a rating of 0. If there was risk of bias in just 1 domain, the risk of  
8 bias was given a 'serious' rating of -1, but if there was risk of bias in 2 or more domains the  
9 risk of bias was given a 'very serious' rating of -2. A weighted average score was then  
10 calculated across all studies contributing to the outcome, by taking into account the weighting  
11 of studies according to study precision. For example if the most precise studies tended to  
12 each have a score of -1 for that outcome, the overall score for that outcome would tend  
13 towards -1.

14 **Table 3: Principle domains of bias in randomised controlled trials**

Limitation	Explanation
Selection bias (sequence generation and allocation concealment)	If those enrolling patients are aware of the group to which the next enrolled patient will be allocated, either because of a non-random sequence that is predictable, or because a truly random sequence was not concealed from the researcher, this may translate into systematic selection bias. This may occur if the researcher chooses not to recruit a participant into that specific group because of: <ul style="list-style-type: none"> <li>• knowledge of that participant's likely prognostic characteristics, and</li> <li>• a desire for one group to do better than the other.</li> </ul>
Performance and detection bias (lack of blinding of patients and healthcare professionals)	Patients, caregivers, those adjudicating or recording outcomes, and data analysts should not be aware of the arm to which patients are allocated. Knowledge of the group can influence: <ul style="list-style-type: none"> <li>• the experience of the placebo effect</li> <li>• performance in outcome measures</li> <li>• the level of care and attention received, and</li> <li>• the methods of measurement or analysis</li> </ul> all of which can contribute to systematic bias.
Attrition bias	Attrition bias results from an unaccounted for loss of data beyond a certain level (a differential of 10% between groups). Loss of data can occur when participants are compulsorily withdrawn from a group by the researchers (for example, when a per-protocol approach is used) or when participants do not attend assessment sessions. If the missing data are likely to be different from the data of those remaining in the groups, and there is a differential rate of such missing data from groups, systematic attrition bias may result.
Selective outcome reporting	Reporting of some outcomes and not others on the basis of the results can also lead to bias, as this may distort the overall impression of efficacy.
Other limitations	For example: <ul style="list-style-type: none"> <li>• Stopping early for benefit observed in randomised trials, in particular in the absence of adequate stopping rules.</li> <li>• Use of unvalidated patient-reported outcome measures.</li> <li>• Lack of washout periods to avoid carry-over effects in crossover trials.</li> <li>• Recruitment bias in cluster-randomised trials.</li> </ul>

1        *The assessment of risk of bias differs for non-randomised intervention studies, as they are*  
2        *inherently at high risk of selection bias. For this reason, GRADE requires that non-*  
3        *randomised evidence is initially downgraded on the basis of study design, starting with a*  
4        *rating of –2. This accounts for selection bias and so non-randomised intervention studies are*  
5        *not downgraded any further on that domain. Non-randomised evidence was assessed*  
6        *against the remaining domains used for RCTs in Table 3, and downgraded further as*  
7        *appropriate.*

#### 82.3.4.1.2 **Indirectness**

9        Indirectness refers to the extent to which the populations, interventions, comparisons and  
10       outcome measures are dissimilar to those defined in the inclusion criteria for the reviews.  
11       Indirectness is important when these differences are expected to contribute to a difference in  
12       effect size, or may affect the balance of harms and benefits considered for an intervention.  
13       As for the risk of bias, each outcome had its indirectness assessed within each study first.  
14       For each study, if there were no sources of indirectness, indirectness was given a rating of 0.  
15       If there was indirectness in just 1 source (for example in terms of population), indirectness  
16       was given a ‘serious’ rating of –1, but if there was indirectness in 2 or more sources (for  
17       example, in terms of population and treatment) the indirectness was given a ‘very serious’  
18       rating of –2. A weighted average score was then calculated across all studies contributing to  
19       the outcome by taking into account study precision. For example, if the most precise studies  
20       tended to have an indirectness score of –1 each for that outcome, the overall score for that  
21       outcome would tend towards –1.

#### 222.3.4.1.3 **Inconsistency**

23       Inconsistency refers to an unexplained heterogeneity of results for an outcome across  
24       different studies. When estimates of the treatment effect across studies differ widely, this  
25       suggests true differences in the underlying treatment effect, which may be due to differences  
26       in populations, settings or doses. When heterogeneity existed within an outcome (chi-  
27       squared  $p < 0.1$ , or  $I^2 > 50\%$ ), but no plausible explanation could be found, the quality of  
28       evidence for that outcome was downgraded. Inconsistency for that outcome was given a  
29       ‘serious’ score of –1 if the  $I^2$  was 50–74%, and a ‘very serious’ score of –2 if the  $I^2$  was 75%  
30       or more.

31       If inconsistency could be explained based on pre specified subgroup analysis (that is, each  
32       subgroup had an  $I^2 < 50\%$ ), the committee took this into account and considered whether to  
33       make separate recommendations on new outcomes based on the subgroups defined by the  
34       assumed explanatory factors. In such a situation the quality of evidence was not downgraded  
35       for those emergent outcomes.

36       Since the inconsistency score was based on the meta-analysis results, the score  
37       represented the whole outcome and so weighted averaging across studies was not  
38       necessary.

#### 392.3.4.1.4 **Imprecision**

40       The criteria applied for imprecision were based on the 95% CIs for the pooled estimate of  
41       effect, and the minimal important differences (MID) for the outcome. The MIDs are the  
42       threshold for appreciable benefits and harms, separated by a zone either side of the line of  
43       no effect where there is assumed to be no clinically important effect. If either end of the 95%  
44       CI of the overall estimate of effect crossed 1 of the MID lines, imprecision was regarded as  
45       serious and a ‘serious’ score of –1 was given. This was because the overall result, as  
46       represented by the span of the confidence interval, was consistent with 2 interpretations as  
47       defined by the MID (for example, both no clinically important effect and clinical benefit were  
48       possible interpretations). If both MID lines were crossed by either or both ends of the 95% CI  
49       then imprecision was regarded as very serious and a ‘very serious’ score of –2 was given.  
50       This was because the overall result was consistent with all 3 interpretations defined by the

1 MID (no clinically important effect, clinical benefit and clinical harm). This is illustrated in  
2 Figure 2. As for inconsistency, since the imprecision score was based on the meta-analysis  
3 results, the score represented the whole outcome and so weighted averaging across studies  
4 was not necessary.

5 The position of the MID lines is ideally determined by values reported in the literature.  
6 'Anchor-based' methods aim to establish clinically meaningful changes in a continuous  
7 outcome variable by relating or 'anchoring' them to patient-centred measures of clinical  
8 effectiveness that could be regarded as gold standards with a high level of face validity. For  
9 example, a MID for an outcome could be defined by the minimum amount of change in that  
10 outcome necessary to make patients feel their quality of life had 'significantly improved'.  
11 MIDs in the literature may also be based on expert clinician or consensus opinion concerning  
12 the minimum amount of change in a variable deemed to affect quality of life or health. For  
13 binary variables, any MIDs reported in the literature will inevitably be based on expert  
14 consensus, as such MIDs relate to all-or-nothing population effects rather than measurable  
15 effects on an individual, and so are not amenable to patient-centred 'anchor' methods.


16 In the absence of values identified in the literature, the alternative approach to deciding on  
17 MID levels is the 'default' method, as follows:

- 18 • For categorical outcomes the MIDs were taken to be RRs of 0.8 and 1.25. For 'positive'  
19 outcomes such as 'patient satisfaction', the RR of 0.8 is taken as the line denoting the  
20 boundary between no clinically important effect and a clinically significant harm, whilst the  
21 RR of 1.25 is taken as the line denoting the boundary between no clinically important  
22 effect and a clinically significant benefit. For 'negative' outcomes such as 'bleeding', the  
23 opposite occurs, so the RR of 0.8 is taken as the line denoting the boundary between no  
24 clinically important effect and a clinically significant benefit, whilst the RR of 1.25 is taken  
25 as the line denoting the boundary between no clinically important effect and a clinically  
26 significant harm.
- 27 • For mortality any change was considered to be clinically important and the imprecision  
28 was assessed on the basis of the whether the confidence intervals crossed the line of no  
29 effect that is whether the result was consistent with both benefit and harm.
- 30 • For continuous outcome variables the MID was taken as half the median baseline  
31 standard deviation of that variable, across all studies in the meta-analysis. Hence the MID  
32 denoting the minimum clinically significant benefit was positive for a 'positive' outcome (for  
33 example, a quality of life measure where a higher score denotes better health), and  
34 negative for a 'negative' outcome (for example, a visual analogue scale [VAS] pain score).  
35 Clinically significant harms will be the converse of these. If baseline values are  
36 unavailable, then half the median comparator group standard deviation of that variable will  
37 be taken as the MID.
- 38 • If standardised mean differences have been used, then the MID will be set at the absolute  
39 value of +0.5. This follows because standardised mean differences are mean differences  
40 normalised to the pooled standard deviation of the 2 groups, and are thus effectively  
41 expressed in units of 'numbers of standard deviations'. The 0.5 MID value in this context  
42 therefore indicates half a standard deviation, the same definition of MID as used for non-  
43 standardised mean differences.

44 The default MID value was subject to amendment after discussion with the committee. If the  
45 committee decided that the MID level should be altered, after consideration of absolute as  
46 well as relative effects, this was allowed, provided that any such decision was not influenced  
47 by any bias towards making stronger or weaker recommendations for specific outcomes.

48 For this guideline, no appropriate MIDs for continuous or dichotomous outcomes were found  
49 in the literature, and so the default method was adopted.

**Figure 2:** Illustration of precise and imprecise outcomes based on the 95% CI of dichotomous outcomes in a forest plot (Note that all 3 results would be pooled estimates, and would not, in practice, be placed on the same forest plot)



#### 12.3.4.1.5 Overall grading of the quality of clinical evidence

2 Once an outcome had been appraised for the main quality elements, as above, an overall  
 3 quality grade was calculated for that outcome. The scores (0, -1 or -2) from each of the  
 4 main quality elements were summed to give a score that could be anything from 0 (the best  
 5 possible) to -8 (the worst possible). However scores were capped at -3. This final score was  
 6 then applied to the starting grade that had originally been applied to the outcome by default,  
 7 based on study design. All RCTs started as High and the overall quality became Moderate,  
 8 Low or Very Low if the overall score was -1, -2 or -3 points respectively. The significance of  
 9 these overall ratings is explained in Table 4. The reasons for downgrading in each case were  
 10 specified in the footnotes of the GRADE tables.

11 Non-randomised intervention studies started at Low, and so a score of -1 would be enough  
 12 to take the grade to the lowest level of Very Low. Non-randomised intervention studies could,  
 13 however, be upgraded if there was a large magnitude of effect or a dose-response gradient.

14 **Table 4: Overall quality of outcome evidence in GRADE**

Level	Description
High	Further research is very unlikely to change our confidence in the estimate of effect
Moderate	Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate
Low	Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate
Very low	Any estimate of effect is very uncertain

### 1 2.3.4.2 Prognostic reviews

2 The quality of evidence for prognostic studies was evaluated according to the criteria given in  
3 Table 5. If data were meta-analysed, the quality for pooled studies was presented. If the data  
4 were not pooled, then a quality rating was presented for each study.

5 **Table 5: Description of quality elements for prospective studies**

Quality element	Description of cases where the quality measure would be downgraded
Study design	Case-control studies rather than prospective cohort studies
Patient recruitment	If potential for selection bias
Validity of risk factor measure(s)	If non-validated and no reasonable face validity
Validity of outcome measure	If non-validated and no reasonable face validity
Blinding	If assessors of outcome not blinded to risk factor measurement (or vice versa)
Adequate duration of follow-up (or retrospective duration)	If follow-up (or retrospective) period inadequate to allow events to occur, or retrospective period so short that causality is in doubt because the outcome may have preceded the risk factor
Confounder consideration	If there is a lack of consideration of all reasonable confounders in a multivariable analysis
Attrition	If attrition is too high and there is no attempt to adjust for this
Directness	If the population, risk factors or outcome differ from that in the review question

#### 62.3.4.2.1 Inconsistency

7 Inconsistency was assessed as for intervention studies.

#### 82.3.4.2.2 Imprecision

9 In meta-analysed outcomes, or for non-pooled outcomes, the position of the 95% CIs in  
10 relation to the null line determined the existence of imprecision. If the 95% CI did not cross  
11 the null line then no serious imprecision was recorded. If the 95% CI crossed the null line  
12 then serious imprecision was recorded.

#### 132.3.4.2.3 Overall grading

14 Quality rating started at High for prospective studies, and each major limitation brought the  
15 rating down by 1 increment to a minimum grade of Very Low, as explained for interventional  
16 reviews. For prognostic reviews prospective cohort studies with a multivariate analysis are  
17 regarded as the gold standard because RCTs are usually inappropriate for these types of  
18 review for ethical or pragmatic reasons. Furthermore, if the study is looking at more than 1  
19 risk factor of interest then randomisation would be inappropriate as it can only be applied to 1  
20 of the risk factors.

### 21 2.3.4.3 Diagnostic studies

22 Risk of bias and indirectness of evidence for diagnostic data were evaluated by study using  
23 the Quality Assessment of Diagnostic Accuracy Studies version 2 (QUADAS-2) checklists  
24 (see appendix H in the NICE guidelines manual 2014<sup>4</sup>). Risk of bias and applicability in  
25 primary diagnostic accuracy studies in QUADAS-2 consists of 4 domains (see Figure 3):

- 26 • patient selection
- 27 • index test
- 28 • reference standard

- 1 • flow and timing.

2 **Figure 3: Summary of QUADAS-2 with list of signalling, risk of bias and applicability**  
3 **questions.**

Domain	Patient selection	Index test	Reference standard	Flow and timing
Description	Describe methods of patient selection. Describe included patients (prior testing, presentation, intended use of index test and setting)	Describe the index test and how it was conducted and interpreted	Describe the reference standard and how it was conducted and interpreted	Describe any patients who did not receive the index test(s) and/or reference standard or who were excluded from the 2x2 table (refer to flow diagram). Describe the time interval and any interventions between index test(s) and reference standard
Signalling questions (yes/no/unclear)	Was a consecutive or random sample of patients enrolled?	Were the index test results interpreted without knowledge of the results of the reference standard?	Is the reference standard likely to correctly classify the target condition?	Was there an appropriate interval between index test(s) and reference standard?
	Was a case-control design avoided?	If a threshold was used, was it pre-specified?	Were the reference standard results interpreted without knowledge of the results of the index test?	Did all patients receive a reference standard?
	Did the study avoid inappropriate exclusions?			Did all patients receive the same reference standard?
				Were all patients included in the analysis?
Risk of bias; (high/low/unclear)	Could the selection of patients have introduced bias?	Could the conduct or interpretation of the index test have introduced bias?	Could the reference standard, its conduct or its interpretation have introduced bias?	Could the patient flow have introduced bias?
Concerns regarding applicability (high/low/unclear)	Are there concerns that the included patients do not match the review question?	Are there concerns that the index test, its conduct, or interpretation differ from the review question?	Are there concerns that the target condition as defined by the reference standard does not match the review question?	

#### 42.3.4.3.1 **Inconsistency**

5 Inconsistency refers to an unexplained heterogeneity of results for an outcome across  
6 different studies. Inconsistency was assessed by inspection of the sensitivity value (based on  
7 the primary measure) using the point estimates and 95% CIs of the individual studies on the  
8 forest plots. Particular attention was placed on values above or below 50% (diagnosis based  
9 on chance alone) and the threshold set by the committee (the threshold above which it would

1 be acceptable to recommend a test). For example, the committee might have set a threshold  
2 of 90% as an acceptable level to recommend a test. The evidence was downgraded by 1  
3 increment if the individual studies varied across 2 areas [(for example, 50–90% and 90–  
4 100%)] and by 2 increments if the individual studies varied across 3 areas [(for example, 0–  
5 50%, 50–90% and 90–100%)].

#### 62.3.4.3.2 *Imprecision*

7 The judgement of precision was based on visual inspection of the confidence region around  
8 the summary sensitivity and specificity point from the diagnostic meta-analysis, if a  
9 diagnostic meta-analysis was conducted. Where a diagnostic meta-analysis was not  
10 conducted, imprecision was assessed according to the range of point estimates or, if only  
11 one study contributed to the evidence, the 95% CI around the single study. As a general rule  
12 (after discussion with the committee) a variation of 0–20% was considered precise, 20–40%  
13 serious imprecision, and >40% very serious imprecision. Imprecision was assessed on the  
14 primary outcome measure for decision-making.

#### 152.3.4.3.3 *Overall grading*

16 Quality rating started at High for prospective and retrospective cross-sectional studies, and  
17 each major limitation (risk of bias, indirectness, inconsistency and imprecision) brought the  
18 rating down by 1 increment to a minimum grade of Very Low, as explained for intervention  
19 reviews.

#### 20 2.3.4.4 *Qualitative reviews*

21 Review findings from the included qualitative studies were evaluated and presented using  
22 the ‘Confidence in the Evidence from Reviews of Qualitative Research’ (CERQual) Approach  
23 developed by the GRADE-CERQual Project Group, a subgroup of the GRADE Working  
24 Group.

25 The CERQual Approach assesses the extent to which a review finding is a reasonable  
26 representation of the phenomenon of interest (the focus of the review question). Each review  
27 finding was assessed for each of the 4 quality elements listed and defined below in Table 6.

28 **Table 6: Description of quality elements in GRADE-CERQual for qualitative studies**

Quality element	Description
Methodological limitations	The extent of problems in the design or conduct of the included studies that could decrease the confidence that the review finding is a reasonable representation of the phenomenon of interest. Assessed at the study level using an NGC checklist.
Coherence	The extent to which the reviewer is able to identify a clear pattern across the studies included in the review.
Relevance	The extent to which the body of evidence from the included studies is applicable to the context (study population, phenomenon of interest, setting) specified in the protocol.
Adequacy	The degree of the confidence that the review finding is being supported by sufficient data. This is an overall determination of the richness (depth of analysis) and quantity of the evidence supporting a review finding or theme.

29 Details of how the 4 quality elements (methodological limitations, coherence, relevance and  
30 adequacy) were appraised for each review finding are given below.

#### 312.3.4.4.1 *Methodological limitations*

32 Each review finding had its methodological limitations assessed within each study first using  
33 an NGC checklist. Based on the degree of methodological limitations studies were evaluated

1 as having minor, moderate or severe limitations. The questions to be answered in the  
2 checklist below included:

- 3 • Was qualitative design an appropriate approach?
- 4 • Was the study approved by an ethics committee?
- 5 • Was the study clear in what it sought to do?
- 6 • Is the context clearly described?
- 7 • Is the role of the researcher clearly described?
- 8 • Are the research design and methods rigorous?
- 9 • Was the data collection rigorous?
- 10 • Was the data analysis rigorous?
- 11 • Are the data rich?
- 12 • Are the findings relevant to the aims of the study?
- 13 • Are the findings and conclusions convincing?

14 The overall assessment of the methodological limitations of the evidence was based on the  
15 primary studies contributing to the review finding. The relative contribution of each study to  
16 the overall review finding and the type of methodological limitation(s) were taken into account  
17 when giving an overall rating.

#### 182.3.4.4.2 **Coherence**

19 Coherence is the extent to which the reviewer is able to identify a clear pattern across the  
20 studies included in the review, and if there is variation present (contrasting or disconfirming  
21 data) whether this variation is explained by the contributing study authors. If a review finding  
22 in 1 study does not support the main finding and there is no plausible explanation for this  
23 variation, then the confidence that the main finding reasonably reflects the phenomenon of  
24 interest is decreased. Each review finding was given a rating of minor, moderate or major  
25 concerns about coherence.

#### 262.3.4.4.3 **Relevance**

27 Relevance is the extent to which the body of evidence from the included studies is applicable  
28 to the context (study population, phenomenon of interest, setting) specified in the protocol.  
29 As such, relevance is dependent on the individual review and discussed with the guideline  
30 committee. Relevance is categorised in 3 ways: partial relevance, indirect relevance and no  
31 concerns about relevance.

#### 322.3.4.4.4 **Adequacy**

33 The judgement of adequacy is based on the confidence of the finding being supported by  
34 sufficient data. This is an overall determination of the richness (depth of analysis) and  
35 quantity of the evidence supporting a review finding or theme. Rich data provide sufficient  
36 detail to gain an understanding of the theme or review finding, whereas thin data do not  
37 provide enough detail for an adequate understanding. Quantity of data is the second pillar of  
38 the assessment of adequacy. For review findings that are only supported by 1 study or data  
39 from only a small number of participants, the confidence that the review finding reasonable  
40 represents the phenomenon of interest might be decreased. As with richness of data,  
41 quantity of data is review dependent. Based on the overall judgement of adequacy, a rating  
42 of no concerns, minor concerns, or substantial concerns about adequacy was given.

#### 432.3.4.4.5 **Overall judgement of the level of confidence for a review finding**

44 GRADE-CERQual is used to assess the body of evidence as a whole through a confidence  
45 rating representing the extent to which a review finding is a reasonable representation of the  
46 phenomenon of interest. The 4 components (methodological limitations, coherence,

relevance and adequacy) are used in combination to form an overall judgement. GRADE-CERQual uses 4 levels of confidence: high, moderate, low and very low confidence. The significance of these overall ratings is explained in Table 7. Each review finding starts at a high level of confidence and is downgraded based on the concerns identified in any 1 or more of the 4 components. Quality assessment of qualitative reviews is a subjective judgement by the reviewer based on the concerns that have been noted. A detailed explanation of how such a judgement had been made was included in the narrative summary.

**Table 7: Overall level of confidence for a review finding in GRADE-CERQual**

Level	Description
High confidence	It is highly likely that the review finding is a reasonable representation of the phenomenon of interest.
Moderate confidence	It is likely that the review finding is a reasonable representation of the phenomenon of interest.
Low confidence	It is possible that the review finding is a reasonable representation of the phenomenon of interest.
Very low confidence	It is not clear whether the review finding is a reasonable representation of the phenomenon of interest.

10

### 11 2.3.5 Assessing clinical importance

12 The committee assessed the evidence by outcome in order to determine if there was, or  
13 potentially was, a clinically important benefit, a clinically important harm or no clinically  
14 important difference between interventions. To facilitate this, binary outcomes were  
15 converted into absolute risk differences (ARDs) using GRADEpro<sup>3</sup> software: the median  
16 control group risk across studies was used to calculate the ARD and its 95% CI from the  
17 pooled risk ratio.

18 The assessment of clinical benefit, harm, or no benefit or harm was based on the point  
19 estimate of absolute effect for intervention studies, which was standardised across the  
20 reviews. The committee considered for most of the outcomes in the intervention reviews that  
21 if at least 100 more participants per 1000 (10%) achieved the outcome of interest in the  
22 intervention group compared to the comparison group for a positive outcome then this  
23 intervention was considered beneficial. The same point estimate but in the opposite direction  
24 applied for a negative outcome. For some critical outcomes such as mortality the committee  
25 used tighter clinical importance thresholds such that an absolute difference of less than 10%  
26 would be considered clinically important.

27 This assessment was carried out by the committee for each critical outcome, and an  
28 evidence summary table was produced to compile the committee's assessments of clinical  
29 importance per outcome, alongside the evidence quality and the uncertainty in the effect  
30 estimate (imprecision).

### 31 2.3.6 Clinical evidence statements

32 Clinical evidence statements are summary statements that are included in each evidence  
33 report, and which summarise the key features of the clinical effectiveness evidence  
34 presented. The wording of the evidence statements reflects the certainty or uncertainty in the  
35 estimate of effect. The evidence statements are presented by outcome and they encompass  
36 the following key features of the evidence:

- 37 • The number of studies and the number of participants for a particular outcome.

- 1 • An indication of the direction of clinical importance (if one treatment is beneficial or
- 2 harmful compared to the other, or whether there is no difference between the 2 tested
- 3 treatments).
- 4 • A description of the overall quality of the evidence (GRADE overall quality).

## 5 **2.4 Identifying and analysing evidence of cost effectiveness**

6 The committee is required to make decisions based on the best available evidence of both  
7 clinical effectiveness and cost effectiveness. Guideline recommendations should be based  
8 on the expected costs of the different options in relation to their expected health benefits  
9 (that is, their ‘cost effectiveness’) rather than the total implementation cost. However, the  
10 committee will also need to be increasingly confident in the cost effectiveness of a  
11 recommendation as the cost of implementation increases. Therefore, for recommendations  
12 that are expected to have a substantial impact on resources, the committee will require  
13 robust evidence; any uncertainties must be offset by a compelling argument in favour of the  
14 recommendation. The cost impact or savings potential of a recommendation should not be  
15 the sole reason for the committee’s decision.<sup>4</sup>

16 Health economic evidence was sought relating to the key clinical issues being addressed in  
17 the guideline. Health economists:

- 18 • Undertook a systematic review of the published economic literature.
- 19 • Undertook new cost-effectiveness analysis in priority areas.

### 20 **2.4.1 Literature review**

21 The health economists:

- 22 • Identified potentially relevant studies for each review question from the health economic
- 23 search results by reviewing titles and abstracts. Full papers were then obtained.
- 24 • Reviewed full papers against pre-specified inclusion and exclusion criteria to identify
- 25 relevant studies (see below for details).
- 26 • Critically appraised relevant studies using economic evaluations checklists as specified in
- 27 the NICE guidelines manual.<sup>4</sup>
- 28 • Extracted key information about the studies’ methods and results into health economic
- 29 evidence tables (which can be found in appendices to the relevant evidence reports).
- 30 • Generated summaries of the evidence in NICE health economic evidence profile tables
- 31 (included in the relevant evidence report for each review question) – see below for details.

#### 32 **2.4.1.1 Inclusion and exclusion criteria**

33 Full economic evaluations (studies comparing costs and health consequences of alternative  
34 courses of action: cost–utility, cost-effectiveness, cost–benefit and cost–consequences  
35 analyses) and comparative costing studies that addressed the review question in the relevant  
36 population were considered potentially includable as health economic evidence.

37 Studies are excluded that only report cost per hospital (not per patient) or average cost  
38 effectiveness only without disaggregated costs and effects. Literature reviews, abstracts,  
39 posters, letters, editorials, comment articles, unpublished studies and studies not in English  
40 were excluded. Studies published before 2003 and studies from non-OECD countries or the  
41 USA were also excluded, on the basis that the applicability of such studies to the present UK  
42 NHS context is likely to be too low for them to be helpful for decision-making.

43 Remaining health economic studies were prioritised for inclusion based on their relative  
44 applicability to the development of this guideline and the study limitations. For example, if a  
45 high quality, directly applicable UK analysis was available, then other less relevant studies

1 may not have been included. Where exclusions occurred on this basis, this is noted in the  
2 relevant evidence report.

3 For more details about the assessment of applicability and methodological quality see Table  
4 8 below and the economic evaluation checklist (appendix H of the NICE guidelines manual<sup>4</sup>)  
5 and the health economics review protocol, which can be found in each of the evidence  
6 reports.

7 When no relevant health economic studies were found from the economic literature review,  
8 relevant UK NHS unit costs related to the compared interventions were presented to the  
9 committee to inform the possible economic implications of the recommendations.

#### 10 2.4.1.2 NICE health economic evidence profiles

11 NICE health economic evidence profile tables were used to summarise cost and cost-  
12 effectiveness estimates for the included health economic studies in each evidence review  
13 report. The health economic evidence profile shows an assessment of applicability and  
14 methodological quality for each economic study, with footnotes indicating the reasons for the  
15 assessment. These assessments were made by the health economist using the economic  
16 evaluation checklist from the NICE guidelines manual.<sup>4</sup> It also shows the incremental costs,  
17 incremental effects (for example, quality-adjusted life years [QALYs]) and incremental cost-  
18 effectiveness ratio (ICER) for the base case analysis in the study, as well as information  
19 about the assessment of uncertainty in the analysis. See Table 8 for more details.

20 When a non-UK study was included in the profile, the results were converted into pounds  
21 sterling using the appropriate purchasing power parity.<sup>7</sup>

22 **Table 8: Content of NICE health economic evidence profile**

Item	Description
Study	Surname of first author, date of study publication and country perspective with a reference to full information on the study.
Applicability	An assessment of applicability of the study to this guideline, the current NHS situation and NICE decision-making: <sup>(a)</sup> <ul style="list-style-type: none"> <li>• Directly applicable – the study meets all applicability criteria, or fails to meet 1 or more applicability criteria but this is unlikely to change the conclusions about cost effectiveness.</li> <li>• Partially applicable – the study fails to meet 1 or more applicability criteria, and this could change the conclusions about cost effectiveness.</li> <li>• Not applicable – the study fails to meet 1 or more of the applicability criteria, and this is likely to change the conclusions about cost effectiveness. Such studies would usually be excluded from the review.</li> </ul>
Limitations	An assessment of methodological quality of the study: <sup>(a)</sup> <ul style="list-style-type: none"> <li>• Minor limitations – the study meets all quality criteria, or fails to meet 1 or more quality criteria, but this is unlikely to change the conclusions about cost effectiveness.</li> <li>• Potentially serious limitations – the study fails to meet 1 or more quality criteria, and this could change the conclusions about cost effectiveness.</li> <li>• Very serious limitations – the study fails to meet 1 or more quality criteria, and this is highly likely to change the conclusions about cost effectiveness. Such studies would usually be excluded from the review.</li> </ul>
Other comments	Information about the design of the study and particular issues that should be considered when interpreting it.
Incremental cost	The mean cost associated with one strategy minus the mean cost of a comparator strategy.
Incremental effects	The mean QALYs (or other selected measure of health outcome) associated with one strategy minus the mean QALYs of a comparator strategy.

Item	Description
Cost effectiveness	Incremental cost-effectiveness ratio (ICER): the incremental cost divided by the incremental effects (usually in £ per QALY gained).
Uncertainty	A summary of the extent of uncertainty about the ICER reflecting the results of deterministic or probabilistic sensitivity analyses, or stochastic analyses of trial data, as appropriate.

(a) *Applicability and limitations were assessed using the economic evaluation checklist in appendix H of the NICE guidelines manual<sup>4</sup>*

### 2.4.2 Undertaking new health economic analysis

As well as reviewing the published health economic literature for each review question, as described above, new health economic analysis was undertaken by the health economist in selected areas. Priority areas for new analysis were agreed by the committee after formation of the review questions and consideration of the existing health economic evidence.

Two areas emerged as priorities for original health economic modelling.

- The role of CT in differentiating complicated and uncomplicated acute diverticulitis – see Evidence review: G.
- Laparoscopic lavage versus resectional surgery for people with perforated diverticulitis and purulent peritonitis – see Evidence review: O.

For both questions there is great variation in current practice and there is expected to be a substantial change in resource use arising from the Committee's recommendation.

The following general principles were adhered to in developing the economic analyses.

- Methods were consistent with the NICE reference case for interventions with health outcomes in NHS settings.<sup>4,6</sup>
- The committee was involved in the design of the model, selection of inputs and interpretation of the results.
- Model inputs were based on the systematic review of the clinical literature supplemented with other published data sources where possible.
- When published data were not available, committee expert opinion was used to populate the model.
- Model inputs and assumptions were reported fully and transparently.
- The results were subject to sensitivity analysis and limitations were discussed.
- The model was peer-reviewed by another health economist at the NGC.

Full methods and results of the cost-effectiveness analysis are described in a appendices to the relevant evidence reports – See Evidence reviews G and O.

### 2.4.3 Cost-effectiveness criteria

NICE's report 'Social value judgements: principles for the development of NICE guidance' sets out the principles that committees should consider when judging whether an intervention offers good value for money.<sup>5</sup> In general, an intervention was considered to be cost effective (given that the estimate was considered plausible) if either of the following criteria applied:

- the intervention dominated other relevant strategies (that is, it was both less costly in terms of resource use and more clinically effective compared with all the other relevant alternative strategies), or
- the intervention cost less than £20,000 per QALY gained compared with the next best strategy.

1 If the committee recommended an intervention that was estimated to cost more than £20,000  
2 per QALY gained, or did not recommend one that was estimated to cost less than £20,000  
3 per QALY gained, then the reasons for this decision are discussed explicitly in 'The  
4 committee's discussion of the evidence' section of the relevant evidence report. These  
5 should make reference to issues regarding the plausibility of the estimate or to the factors set  
6 out in 'Social value judgements: principles for the development of NICE guidance'.<sup>5</sup>

7 When QALYs gained are not used in the analysis, results are difficult to interpret unless one  
8 strategy dominates the others with respect to every relevant health outcome and cost.

#### 9 **2.4.4 In the absence of health economic evidence**

10 When no relevant published health economic studies were found, and a new analysis was  
11 not prioritised, the committee made a qualitative judgement about cost effectiveness by  
12 considering expected differences in resource use between options and relevant UK NHS unit  
13 costs, alongside the results of the review of clinical effectiveness evidence.

14 The UK NHS costs reported in the guideline are those that were presented to the committee  
15 and were correct at the time recommendations were drafted. They may have changed  
16 subsequently before the time of publication. However, we have no reason to believe they  
17 have changed substantially.

## 18 **2.5 Formal consensus methods**

### 19 **2.5.1 Introduction**

20 During the development of the guideline a number of systematic reviews identified very  
21 limited or no evidence. In light of this, the committee agreed that additional work would be  
22 carried out to address these areas. This was done to produce a more complete piece of  
23 guidance that would be useful to health professionals who deliver care to people with  
24 diverticular disease.

25 Where there was a lack of published evidence the NGC technical team used a modified  
26 Delphi method (anonymous, multi-round, consensus building technique) based on the NICE  
27 clinical knowledge summary. This type of survey has been used successfully for generating,  
28 analysing and synthesising expert view to reach a group consensus position. The resulting  
29 statements will form the basis for the GC to consider and utilise to develop further  
30 recommendations.

31 The modified Delphi process and areas that are covered by it are:

32 (1) symptoms and signs of suspected diverticular disease (2) symptoms and signs of  
33 suspected acute diverticulitis (3) symptoms and signs of suspected complicated diverticulitis  
34 (Chapter B) (4) management of diverticulosis (5) management of diverticular disease  
35 (Chapter D).

### 36 **2.5.2 Modified Delphi methodology**

37 For review areas where little or no evidence was identified, a modified Delphi survey  
38 method<sup>1, 9</sup> was adopted. In NICE processes, formal consensus techniques (such as the  
39 Delphi method) can be adopted where there is little or no evidence for reviews<sup>4</sup>.

40 Delphi statements were based on NICE clinical knowledge summary (CKS) on diverticular  
41 disease. The NICE CKS service provides primary care practitioners with a readily accessible  
42 summary of the current evidence base and practical guidance on best practice in respect of  
43 over 330 common and/or significant primary care presentations

1 The Delphi panel comprised of registered stakeholders for the NICE diverticular disease  
2 guideline. These covered a wide range of professions and included patient and carer  
3 organisations. Members of the diverticular disease GC also nominated individuals.

4 A survey, consisting of 41 statements plus 3 demographic questions (profession, setting, and  
5 geographic area), was then circulated to the participants. This survey included open text  
6 options in which panel members could give comments to statements. Participants were  
7 asked to comment on and rate how much they agreed with statements via an online survey.  
8 Comments from round 1 were then used to revise and refine the entire set of Delphi  
9 statements as is done in the usual piloting process of survey design. This process was  
10 carried out in conjunction with the GC. 122 panel members, with representatives from all  
11 professions, responded to the survey (n=81 fully completed the survey, n=41 partially  
12 completed the survey).

13 The new survey (round 2) was then sent out to all of the people who responded in round 1. In  
14 round two 57% (69/122) of panel members who took part in the first round responded. For  
15 all the statements (excluding demographics), a Likert scale was applied to indicate the level  
16 of agreement. Some statements employed multiple choice options. A five option Likert scale  
17 was used: strongly disagree, disagree, neither agree or disagree, agree and strongly agree.  
18 A rate of 70% or higher of panel members 'strongly agreeing' or 'agree' was set for rounds 1  
19 and 2. For all questions there was an option 'I do not feel I have the relevant expertise to  
20 answer this question'. These responses were removed from the denominator (to calculate  
21 the percentage in agreement) and excluded from the analysis. Statements that reached  
22 these levels would not feature in the next round. Statements that did not reach this level were  
23 reviewed by the committee and were amended based on the panel's comments in the  
24 survey. This procedure of re-evaluation continued until either the consensus rate was  
25 achieved or until the experts no longer modified their previous estimates / responses (or  
26 comments). There is not complete agreement about the termination of Delphi and one  
27 researcher has stated 'if no consensus emerges, at least a crystallizing of the disparate  
28 positions usually becomes apparent'<sup>2</sup>. When no clear indication was given on how to amend  
29 a statement, and the guideline committee were unable to amend the statement this was  
30 removed from the survey. For example, the statement 'reduce red meat intake' did not reach  
31 agreement, respondents commented that there is no evidence to support this statement and  
32 the guideline committee could not suggest a modification that would address the feedback.  
33 Statements that did not reach agreement but modifications were suggested by the  
34 respondents were re-voted on. How and when consensus was achieved for all statements  
35 is presented in appendix A

### 36 **2.5.3 Qualitative analysis**

37 A free text box was available for panel comments for the statements 'neither agree or  
38 disagree', 'disagree' or strongly disagree. Participants were asked how they would modify the  
39 statement. Members of the panel used these text boxes frequently. The frequency with  
40 which each potential modification to the statement was calculated. The highest frequency  
41 response was chosen to modify the statement. However, frequency was not regarded as the  
42 only indicator for further inclusion the technical team also inspected idiosyncratic responses.  
43 Some comments gave additional or qualifying information to the content of the material.  
44 These were considered on an individual basis by the technical team.

## 45 **2.6 Developing recommendations**

46 Over the course of the guideline development process, the committee was presented with:

- 47 • Summaries of clinical and health economic evidence and quality (as presented in  
48 evidence reports).
- 49 • Evidence tables of the clinical and health economic evidence reviewed from the literature.  
50 All evidence tables can be found in appendices to the relevant evidence reports.

- 1 • Forest plots (in appendices to the relevant evidence reports).  
2 • A description of the methods and results of the cost-effectiveness analyses undertaken for  
3 the guideline.

4 Recommendations were drafted based on the committee's interpretation of the available  
5 evidence, taking into account the balance of benefits, harms and costs between different  
6 courses of action. This was either done formally in an economic model, or informally. Firstly,  
7 the net clinical benefit over harm (clinical effectiveness) was considered, focusing on the  
8 critical outcomes. When this was done informally, the committee took into account the clinical  
9 benefits and harms when one intervention was compared with another. The assessment of  
10 net clinical benefit was moderated by the importance placed on the outcomes (the  
11 committee's values and preferences), and the confidence the committee had in the evidence  
12 (evidence quality). Secondly, the committee assessed whether the net clinical benefit  
13 justified any differences in costs between the alternative interventions.

14 When clinical and health economic evidence was of poor quality, conflicting or absent, the  
15 committee drafted recommendations based on its expert opinion. The considerations for  
16 making consensus-based recommendations include the balance between potential harms  
17 and benefits, the economic costs compared to the economic benefits, current practices,  
18 recommendations made in other relevant guidelines, patient preferences and equality issues.  
19 The consensus recommendations were agreed through discussions in the committee, or  
20 methods of formal consensus through a Delphi survey were applied. A Delphi survey was  
21 used for this guideline where there was an absence of evidence and the committee were  
22 unable to make consensus recommendations. The committee were presented with the  
23 statements that reached consensus in the Delphi survey. These statements were modified  
24 to form recommendations. These modifications did not alter the meaning of the statements  
25 but were made in accordance with NICE guidance on writing recommendations. The  
26 committee also considered whether the uncertainty was sufficient to justify delaying making a  
27 recommendation to await further research, taking into account the potential harm of failing to  
28 make a clear recommendation (see section 2.6.1 below).

29 The committee considered the appropriate 'strength' of each recommendation. This takes  
30 into account the quality of the evidence but is conceptually different. Some recommendations  
31 are 'strong' in that the committee believes that the vast majority of healthcare and other  
32 professionals and patients would choose a particular intervention if they considered the  
33 evidence in the same way that the committee has. This is generally the case if the benefits  
34 clearly outweigh the harms for most people and the intervention is likely to be cost effective.  
35 However, there is often a closer balance between benefits and harms, and some patients  
36 would not choose an intervention whereas others would. This may happen, for example, if  
37 some patients are particularly averse to some side effect and others are not. In these  
38 circumstances, the recommendation is generally weaker, although it may be possible to  
39 make stronger recommendations about specific groups of patients.

40 The committee focused on the following factors in agreeing the wording of the  
41 recommendations:

- 42 • The actions health professionals need to take.  
43 • The information readers need to know.  
44 • The strength of the recommendation (for example the word 'offer' was used for strong  
45 recommendations and 'consider' for weaker recommendations).  
46 • The involvement of patients (and their carers if needed) in decisions on treatment and  
47 care.  
48 • Consistency with NICE's standard advice on recommendations about drugs, waiting times  
49 and ineffective interventions (see section 9.2 in the NICE guidelines manual<sup>4</sup>).

50 The main considerations specific to each recommendation are outlined in 'The committee's  
51 discussion of the evidence' section within each evidence report.

1 **2.6.1 Research recommendations**

2 When areas were identified for which good evidence was lacking, the committee considered  
3 making recommendations for future research. Decisions about the inclusion of a research  
4 recommendation were based on factors such as:

- 5 • the importance to patients or the population
- 6 • national priorities
- 7 • potential impact on the NHS and future NICE guidance
- 8 • ethical and technical feasibility.

9 **2.6.2 Validation process**

10 This guidance is subject to a 6-week public consultation and feedback as part of the quality  
11 assurance and peer review of the document. All comments received from registered  
12 stakeholders are responded to in turn and posted on the NICE website.

13 **2.6.3 Updating the guideline**

14 Following publication, and in accordance with the NICE guidelines manual, NICE will  
15 undertake a review of whether the evidence base has progressed significantly to alter the  
16 guideline recommendations and warrant an update.

17 **2.6.4 Disclaimer**

18 Healthcare providers need to use clinical judgement, knowledge and expertise when  
19 deciding whether it is appropriate to apply guidelines. The recommendations cited here are a  
20 guide and may not be appropriate for use in all situations. The decision to adopt any of the  
21 recommendations cited here must be made by practitioners in light of individual patient  
22 circumstances, the wishes of the patient, clinical expertise and resources.

23 The National Guideline Centre disclaims any responsibility for damages arising out of the use  
24 or non-use of this guideline and the literature used in support of this guideline.

25 **2.6.5 Funding**

26 The National Guideline Centre was commissioned by the National Institute for Health and  
27 Care Excellence to undertake the work on this guideline.

28

29

30

### 1 3 Acronyms and abbreviations

Acronym or abbreviation	Description
ASA	American Society of Anesthesiologists
AUC	Area under curve
BMI	Body mass index
CI	Confidence interval
CRP	C-reactive protein
CT	Computed tomography
CUA	Cost-utility analysis
GC	Guideline committee
GRADE	Grading of Recommendations Assessment, Development and Evaluation
IBS	Irritable bowel syndrome
ICER	Incremental cost-effectiveness ratio
IV	Intravenous
MD	Mean difference
MID	Minimal clinically important difference
MRI	Magnetic resonance imaging
NA	Not applicable
NGC	National Guideline Centre
NICE	National Institute for Health and Care Excellence
NPV	Negative predictive value
NSAIDs	Non-steroidal anti-inflammatory drugs
OECD	Organisation for Economic Co-operation and Development
OR	Odds ratio
PICO	Population, intervention, comparison, outcome
PPV	Positive predictive value
QALY	Quality-adjusted life years
ROC	Receiver operating characteristic
RR	Risk ratio/relative risk
SE	Standard error
SUDD	Symptomatic uncomplicated diverticular disease
US	Ultrasound
UTI	Urinary tract infection

## 4 Glossary

The NICE Glossary can be found at [www.nice.org.uk/glossary](http://www.nice.org.uk/glossary).

### 4.1 Guideline-specific terms

Term	Definition
Abscess	A collection of pus within a well-defined, pocket-like area, usually caused by bacterial infection. Diverticular abscesses are considered to be a complication of diverticulitis and develop along the wall of the colon.
Acute diverticulitis	Inflammation or infection associated with diverticula.
Anastomosis (primary/secondary)	The joining of bowel back together following partial colectomy. Anastomosis may be primary if the bowel is immediately joined back together or secondary if a stoma is fitted following colectomy and the bowel re-joined in a second operation at a later date.
Anastomotic leak	The leakage of bowel contents following an attempt at anastomosis after resection of bowel.
Barium enema	X-ray procedure used to detect abnormalities or alterations in the colon.
Colectomy	Surgical removal of all or part of the colon.
Colonoscopy	An endoscopic procedure that allows the colon to be visualised using a flexible tube with a camera attached.
Compliant bowel	Bowel that is functional and is not restricted in terms of movement. Compliant bowel may still contain diverticula.
Complicated acute diverticulitis	The presence of complications associated with inflamed or infected diverticula. These complications may include abscess, fistula, stricture and perforation.
Computed tomography	A type of scan that uses X-rays and a computer to produce detailed images of structures inside the body. May be performed with or without contrast.
CT colonography/CT colonoscopy	A procedure that involves the use of a CT scanner to produce three-dimensional images of the large bowel and rectum. Less invasive procedure than colonoscopy.
Diverticula (singular, diverticulum)	Small pouches that protrude from the walls of the large intestine.
Diverticular disease (uncomplicated)	The presence of diverticula with mild abdominal pain or tenderness and no systemic symptoms.
Diverticulosis	The presence of colonic diverticula unaccompanied by inflammation or resulting symptoms. Diverticulosis is identified in many cases as a result of screening for other conditions and is not associated with symptoms itself.
Faecaluria	The presence of faeces in the urine.
Faecal peritonitis	Peritonitis associated with the presence of faeces in the abdominal (peritoneal) cavity.
Fistula	An abnormal connection that forms between two organs or between an organ and the skin. This is considered to be a complication of diverticulitis and an example of a fistula that may occur as a result of this condition is an abnormal connection between the colon and bladder.
Flexible sigmoidoscopy	Procedure that employs a flexible, narrow tube with a light and camera on one end to visualise lower regions of the colon - the sigmoid and

Term	Definition
	descending colon.
Generalised peritonitis	This term describes the extent of peritonitis within the abdominal (peritoneal) cavity. Generalised peritonitis refers to peritonitis that is not limited to a particular area of the colon where the infection originated but is diffuse, affecting a larger area of the cavity than in localised peritonitis. This leads to severe pain, fever and tachycardia with a rigid abdomen.
Hartmann's procedure	An operation that involves resection of part of the recto-sigmoid colon with formation of an end colostomy. The end colostomy may be temporary or permanent.
Hinchey staging (I-IV)	A system used to classify perforations of the colon, which also includes abscesses, and indicates the severity of the perforation. Stages I and II refer to phlegmon/pericolic abscesses and pelvic abscesses, respectively, while stages III and IV refer to generalised purulent and generalised faecal peritonitis, respectively. Note there are various modifications of the Hinchey classification that differ slightly in terms of classification structure.
Ileostomy	A type of stoma where the small intestine is diverted through an opening in the abdomen.
Laparoscopic lavage	A procedure that is performed laparoscopically and in diverticulitis involves the washing of the abdominal cavity with water or medicated solution.
Laparoscopy	Surgical procedure that allows surgeons access to the abdomen and pelvis without requiring large incisions into the skin. Also termed keyhole or minimally invasive surgery.
Laparotomy	Surgical procedure that involves a large incision into the abdominal wall to gain access into the abdominal cavity.
Left iliac fossa	A term often used to describe the location of pain in those with diverticular disease or diverticulitis, referring to the left lower quadrant of the abdomen. This anatomical region comprises the descending and sigmoid colon, and in women also covers internal reproductive organs.
Localised peritonitis	This term describes the extent of peritonitis within the abdominal (peritoneal) cavity. Localised peritonitis refers to peritonitis that is confined within a certain area of the cavity that surrounds the source of the infection, for example a perforation of the colon. The infection affects a smaller area of the cavity compared with generalised peritonitis.
MRI	A type of scan that uses magnetic fields and radio waves to produce detailed images of structures inside the body.
Obstruction	In diverticulitis, intestinal obstruction may occur, which blocks the affected region of the colon and is commonly the result of a stricture. This blockage of the colon prevents the passing of any flatulence or stool.
Percutaneous drainage	A method of draining abscesses that uses imaging to guide the insertion of a catheter or needle to remove or drain infected fluid.
Perforation	Perforations, the formation of holes in the wall of the bowel, may develop as a complication of diverticulitis. If large enough, these allow the contents of the colon to leak into the abdominal (peritoneal) cavity and the subsequent development of peritonitis.
Peritonitis	Inflammation and infection of the peritoneum, the thin layer of tissue that lines the inside of the abdomen, and within the abdominal (peritoneal) cavity. This is considered to be a complication of diverticulitis and is a result of leakage of colon contents into the abdominal cavity. See separate definitions for purulent, faecal, generalised and localised peritonitis.

Term	Definition
Phlegmon	A phlegmon refers to an infected area with the presence of pus that can occur within the colon as a complication of diverticulitis. It is similar to an abscess but is within a less well-defined area and may be spread over a larger area.
Pneumaturia	The passage of gas in the urine, indicated by the presence of air bubbles in the urine.
Purulent peritonitis	Peritonitis that is associated with the presence of pus only (no faeces) in the abdominal (peritoneal) cavity.
Pyuria	The presence of pus in the urine.
Recurrent diverticulitis	Recurrent episodes of acute diverticulitis.
Sigmoid colon	Terminal S-shaped section of the colon that connects the descending colon to the rectum
Sigmoidectomy	Surgical removal of all or part of the sigmoid colon.
Stricture	A complication of diverticulitis that involves the severe narrowing of the colon that can occur as a result of inflammation and scarring. This narrowing results in the slowing of the passage of bowel contents or its obstruction.
Stoma	An artificial opening that can be created following surgery on the digestive or urinary tract and collects urine or faeces for disposal.
Ultrasound	A type of scan that employs high-frequency sound waves to produce an image of a region inside the body.

## 1 4.2 General terms

2

Term	Definition
Abstract	Summary of a study, which may be published alone or as an introduction to a full scientific paper.
Algorithm (in guidelines)	A flow chart of the clinical decision pathway described in the guideline, where decision points are represented with boxes, linked with arrows.
Allocation concealment	The process used to prevent advance knowledge of group assignment in an RCT. The allocation process should be impervious to any influence by the individual making the allocation, by being administered by someone who is not responsible for recruiting participants.
Applicability	How well the results of a study or NICE evidence review can answer a clinical question or be applied to the population being considered.
Arm (of a clinical study)	Subsection of individuals within a study who receive one particular intervention, for example placebo arm.
Association	Statistical relationship between 2 or more events, characteristics or other variables. The relationship may or may not be causal.
Base case analysis	In an economic evaluation, this is the main analysis based on the most plausible estimate of each input. In contrast, see Sensitivity analysis.
Baseline	The initial set of measurements at the beginning of a study (after run-in period where applicable), with which subsequent results are compared.
Bayesian analysis	A method of statistics, where a statistic is estimated by combining established information or belief (the 'prior') with new evidence (the 'likelihood') to give a revised estimate (the 'posterior').
Before-and-after study	A study that investigates the effects of an intervention by measuring particular characteristics of a population both before and after taking

Term	Definition
	the intervention, and assessing any change that occurs.
Bias	Influences on a study that can make the results look better or worse than they really are. (Bias can even make it look as if a treatment works when it does not.) Bias can occur by chance, deliberately or as a result of systematic errors in the design and execution of a study. It can also occur at different stages in the research process, for example, during the collection, analysis, interpretation, publication or review of research data. For examples see selection bias, performance bias, information bias, confounding factor, and publication bias.
Blinding	<p>A way to prevent researchers, doctors and patients in a clinical trial from knowing which study group each patient is in so they cannot influence the results. The best way to do this is by sorting patients into study groups randomly. The purpose of 'blinding' or 'masking' is to protect against bias.</p> <p>A single-blinded study is one in which patients do not know which study group they are in (for example whether they are taking the experimental drug or a placebo). A double-blinded study is one in which neither patients nor the researchers and doctors know which study group the patients are in. A triple blind study is one in which neither the patients, clinicians or the people carrying out the statistical analysis know which treatment patients received.</p>
Carer (caregiver)	Someone who looks after family, partners or friends in need of help because they are ill, frail or have a disability.
Case–control study	<p>A study to find out the cause(s) of a disease or condition. This is done by comparing a group of patients who have the disease or condition (cases) with a group of people who do not have it (controls) but who are otherwise as similar as possible (in characteristics thought to be unrelated to the causes of the disease or condition). This means the researcher can look for aspects of their lives that differ to see if they may cause the condition.</p> <p>For example, a group of people with lung cancer might be compared with a group of people the same age that do not have lung cancer. The researcher could compare how long both groups had been exposed to tobacco smoke. Such studies are retrospective because they look back in time from the outcome to the possible causes of a disease or condition.</p>
Case series	Report of a number of cases of a given disease, usually covering the course of the disease and the response to treatment. There is no comparison (control) group of patients.
Clinical efficacy	The extent to which an intervention is active when studied under controlled research conditions.
Clinical effectiveness	<p>How well a specific test or treatment works when used in the 'real world' (for example, when used by a doctor with a patient at home), rather than in a carefully controlled clinical trial. Trials that assess clinical effectiveness are sometimes called management trials.</p> <p>Clinical effectiveness is not the same as efficacy.</p>
Clinician	A healthcare professional who provides patient care. For example, a doctor, nurse or physiotherapist.
Cochrane Review	The Cochrane Library consists of a regularly updated collection of evidence-based medicine databases including the Cochrane Database of Systematic Reviews (reviews of randomised controlled trials prepared by the Cochrane Collaboration).
Cohort study	A study with 2 or more groups of people – cohorts – with similar characteristics. One group receives a treatment, is exposed to a risk factor or has a particular symptom and the other group does not. The

Term	Definition
	study follows their progress over time and records what happens. See also observational study.
Comorbidity	A disease or condition that someone has in addition to the health problem being studied or treated.
Comparability	Similarity of the groups in characteristics likely to affect the study results (such as health status or age).
Concordance	This is a recent term whose meaning has changed. It was initially applied to the consultation process in which doctor and patient agree therapeutic decisions that incorporate their respective views, but now includes patient support in medicine taking as well as prescribing communication. Concordance reflects social values but does not address medicine-taking and may not lead to improved adherence.
Confidence interval (CI)	<p>There is always some uncertainty in research. This is because a small group of patients is studied to predict the effects of a treatment on the wider population. The confidence interval is a way of expressing how certain we are about the findings from a study, using statistics. It gives a range of results that is likely to include the 'true' value for the population.</p> <p>The CI is usually stated as '95% CI', which means that the range of values has a 95 in a 100 chance of including the 'true' value. For example, a study may state that "based on our sample findings, we are 95% certain that the 'true' population blood pressure is not higher than 150 and not lower than 110". In such a case the 95% CI would be 110 to 150.</p> <p>A wide confidence interval indicates a lack of certainty about the true effect of the test or treatment – often because a small group of patients has been studied. A narrow confidence interval indicates a more precise estimate (for example, if a large number of patients have been studied).</p>
Confounding factor	<p>Something that influences a study and can result in misleading findings if it is not understood or appropriately dealt with.</p> <p>For example, a study of heart disease may look at a group of people that exercises regularly and a group that does not exercise. If the ages of the people in the 2 groups are different, then any difference in heart disease rates between the 2 groups could be because of age rather than exercise. Therefore age is a confounding factor.</p>
Consensus methods	Techniques used to reach agreement on a particular issue. Consensus methods may be used to develop NICE guidance if there is not enough good quality research evidence to give a clear answer to a question. Formal consensus methods include Delphi and nominal group techniques.
Control group	<p>A group of people in a study who do not receive the treatment or test being studied. Instead, they may receive the standard treatment (sometimes called 'usual care') or a dummy treatment (placebo). The results for the control group are compared with those for a group receiving the treatment being tested. The aim is to check for any differences.</p> <p>Ideally, the people in the control group should be as similar as possible to those in the treatment group, to make it as easy as possible to detect any effects due to the treatment.</p>
Cost–benefit analysis (CBA)	Cost–benefit analysis is one of the tools used to carry out an economic evaluation. The costs and benefits are measured using the same monetary units (for example, pounds sterling) to see whether the benefits exceed the costs.
Cost–consequences analysis (CCA)	Cost–consequences analysis is one of the tools used to carry out an economic evaluation. This compares the costs (such as treatment and hospital care) and the consequences (such as health outcomes)

Term	Definition
	of a test or treatment with a suitable alternative. Unlike cost–benefit analysis or cost-effectiveness analysis, it does not attempt to summarise outcomes in a single measure (like the quality-adjusted life year) or in financial terms. Instead, outcomes are shown in their natural units (some of which may be monetary) and it is left to decision-makers to determine whether, overall, the treatment is worth carrying out.
Cost-effectiveness analysis (CEA)	Cost-effectiveness analysis is one of the tools used to carry out an economic evaluation. The benefits are expressed in non-monetary terms related to health, such as symptom-free days, heart attacks avoided, deaths avoided or life years gained (that is, the number of years by which life is extended as a result of the intervention).
Cost-effectiveness model	An explicit mathematical framework, which is used to represent clinical decision problems and incorporate evidence from a variety of sources in order to estimate the costs and health outcomes.
Cost–utility analysis (CUA)	Cost–utility analysis is one of the tools used to carry out an economic evaluation. The benefits are assessed in terms of both quality and duration of life, and expressed as quality-adjusted life years (QALYs). See also utility.
Credible interval (CrI)	The Bayesian equivalent of a confidence interval.
Decision analysis	An explicit quantitative approach to decision-making under uncertainty, based on evidence from research. This evidence is translated into probabilities, and then into diagrams or decision trees which direct the clinician through a succession of possible scenarios, actions and outcomes.
Deterministic analysis	In economic evaluation, this is an analysis that uses a point estimate for each input. In contrast, see Probabilistic analysis
Diagnostic odds ratio	The diagnostic odds ratio is a measure of the effectiveness of a diagnostic test. It is defined as the ratio of the odds of the test being positive if the subject has a disease relative to the odds of the test being positive if the subject does not have the disease.
Discounting	Costs and perhaps benefits incurred today have a higher value than costs and benefits occurring in the future. Discounting health benefits reflects individual preference for benefits to be experienced in the present rather than the future. Discounting costs reflects individual preference for costs to be experienced in the future rather than the present.
Disutility	The loss of quality of life associated with having a disease or condition. See Utility
Dominance	A health economics term. When comparing tests or treatments, an option that is both less effective and costs more is said to be ‘dominated’ by the alternative.
Drop-out	A participant who withdraws from a trial before the end.
Economic evaluation	An economic evaluation is used to assess the cost effectiveness of healthcare interventions (that is, to compare the costs and benefits of a healthcare intervention to assess whether it is worth doing). The aim of an economic evaluation is to maximise the level of benefits – health effects – relative to the resources available. It should be used to inform and support the decision-making process; it is not supposed to replace the judgement of healthcare professionals.  There are several types of economic evaluation: cost–benefit analysis, cost–consequences analysis, cost-effectiveness analysis, cost-minimisation analysis and cost–utility analysis. They use similar methods to define and evaluate costs, but differ in the way they estimate the benefits of a particular drug, programme or intervention.
Effect	A measure that shows the magnitude of the outcome in one group

Term	Definition
(as in effect measure, treatment effect, estimate of effect, effect size)	<p>compared with that in a control group.</p> <p>For example, if the absolute risk reduction is shown to be 5% and it is the outcome of interest, the effect size is 5%.</p> <p>The effect size is usually tested, using statistics, to find out how likely it is that the effect is a result of the treatment and has not just happened by chance (that is, to see if it is statistically significant).</p>
Effectiveness	How beneficial a test or treatment is under usual or everyday conditions, compared with doing nothing or opting for another type of care.
Efficacy	How beneficial a test, treatment or public health intervention is under ideal conditions (for example, in a laboratory), compared with doing nothing or opting for another type of care.
Epidemiological study	The study of a disease within a population, defining its incidence and prevalence and examining the roles of external influences (for example, infection, diet) and interventions.
EQ-5D (EuroQol 5 dimensions)	A standardised instrument used to measure health-related quality of life. It provides a single index value for health status.
Evidence	Information on which a decision or guidance is based. Evidence is obtained from a range of sources including randomised controlled trials, observational studies, expert opinion (of clinical professionals or patients).
Exclusion criteria (literature review)	Explicit standards used to decide which studies should be excluded from consideration as potential sources of evidence.
Exclusion criteria (clinical study)	Criteria that define who is not eligible to participate in a clinical study.
Extended dominance	If Option A is both more clinically effective than Option B and has a lower cost per unit of effect, when both are compared with a do-nothing alternative then Option A is said to have extended dominance over Option B. Option A is therefore cost effective and should be preferred, other things remaining equal.
Extrapolation	An assumption that the results of studies of a specific population will also hold true for another population with similar characteristics.
Follow-up	Observation over a period of time of an individual, group or initially defined population whose appropriate characteristics have been assessed in order to observe changes in health status or health-related variables.
Generalisability	The extent to which the results of a study hold true for groups that did not participate in the research. See also external validity.
Gold standard	A method, procedure or measurement that is widely accepted as being the best available to test for or treat a disease.
GRADE, GRADE profile	A system developed by the GRADE Working Group to address the shortcomings of present grading systems in healthcare. The GRADE system uses a common, sensible and transparent approach to grading the quality of evidence. The results of applying the GRADE system to clinical trial data are displayed in a table known as a GRADE profile.
Harms	Adverse effects of an intervention.
Health economics	Study or analysis of the cost of using and distributing healthcare resources.
Health-related quality of life (HRQoL)	A measure of the effects of an illness to see how it affects someone's day-to-day life.
Heterogeneity or Lack of homogeneity	The term is used in meta-analyses and systematic reviews to describe when the results of a test or treatment (or estimates of its effect) differ significantly in different studies. Such differences may

Term	Definition
	occur as a result of differences in the populations studied, the outcome measures used or because of different definitions of the variables involved. It is the opposite of homogeneity.
Imprecision	Results are imprecise when studies include relatively few patients and few events and thus have wide confidence intervals around the estimate of effect.
Inclusion criteria (literature review)	Explicit criteria used to decide which studies should be considered as potential sources of evidence.
Incremental analysis	The analysis of additional costs and additional clinical outcomes with different interventions.
Incremental cost	The extra cost linked to using one test or treatment rather than another. Or the additional cost of doing a test or providing a treatment more frequently.
Incremental cost-effectiveness ratio (ICER)	The difference in the mean costs in the population of interest divided by the differences in the mean outcomes in the population of interest for one treatment compared with another.
Incremental net benefit (INB)	The value (usually in monetary terms) of an intervention net of its cost compared with a comparator intervention. The INB can be calculated for a given cost-effectiveness (willingness to pay) threshold. If the threshold is £20,000 per QALY gained then the INB is calculated as: $(£20,000 \times \text{QALYs gained}) - \text{Incremental cost}$ .
Indirectness	The available evidence is different to the review question being addressed, in terms of PICO (population, intervention, comparison and outcome).
Intention-to-treat analysis (ITT)	An assessment of the people taking part in a clinical trial, based on the group they were initially (and randomly) allocated to. This is regardless of whether or not they dropped out, fully complied with the treatment or switched to an alternative treatment. Intention-to-treat analyses are often used to assess clinical effectiveness because they mirror actual practice: that is, not everyone complies with treatment and the treatment people receive may be changed according to how they respond to it.
Intervention	In medical terms this could be a drug treatment, surgical procedure, diagnostic or psychological therapy. Examples of public health interventions could include action to help someone to be physically active or to eat a more healthy diet.
Intraoperative	The period of time during a surgical procedure.
Kappa statistic	A statistical measure of inter-rater agreement that takes into account the agreement occurring by chance.
Length of stay	The total number of days a participant stays in hospital.
Licence	See 'Product licence'.
Life years gained	Mean average years of life gained per person as a result of the intervention compared with an alternative intervention.
Likelihood ratio	The likelihood ratio combines information about the sensitivity and specificity. It tells you how much a positive or negative result changes the likelihood that a patient would have the disease. The likelihood ratio of a positive test result (LR+) is sensitivity divided by (1 minus specificity).
Long-term care	Residential care in a home that may include skilled nursing care and help with everyday activities. This includes nursing homes and residential homes.
Logistic regression or Logit model	In statistics, logistic regression is a type of analysis used for predicting the outcome of a binary dependent variable based on one or more predictor variables. It can be used to estimate the log of the odds (known as the 'logit').

Term	Definition
Loss to follow-up	A patient, or the proportion of patients, actively participating in a clinical trial at the beginning, but whom the researchers were unable to trace or contact by the point of follow-up in the trial
Markov model	A method for estimating long-term costs and effects for recurrent or chronic conditions, based on health states and the probability of transition between them within a given time period (cycle).
Meta-analysis	A method often used in systematic reviews. Results from several studies of the same test or treatment are combined to estimate the overall effect of the treatment.
Multivariate model	A statistical model for analysis of the relationship between 2 or more predictor (independent) variables and the outcome (dependent) variable.
Negative predictive value (NPV)	In screening or diagnostic tests: A measure of the usefulness of a screening or diagnostic test. It is the proportion of those with a negative test result who do not have the disease, and can be interpreted as the probability that a negative test result is correct. It is calculated as follows: $TN/(TN+FN)$
Net monetary benefit (NMB)	The value in monetary terms of an intervention net of its cost. The NMB can be calculated for a given cost-effectiveness threshold. If the threshold is £20,000 per QALY gained then the NMB for an intervention is calculated as: $(£20,000 \times \text{mean QALYs}) - \text{mean cost}$ . The most preferable option (that is, the most clinically effective option to have an ICER below the threshold selected) will be the treatment with the highest NMB.
Non-randomised intervention study	A quantitative study investigating the effectiveness of an intervention that does not use randomisation to allocate patients (or units) to treatment groups. Non-randomised studies include observational studies, where allocation to groups occurs through usual treatment decisions or people's preferences. Non-randomised studies can also be experimental, where the investigator has some degree of control over the allocation of treatments.  Non-randomised intervention studies can use a number of different study designs, and include cohort studies, case-control studies, controlled before-and-after studies, interrupted-time-series studies and quasi-randomised controlled trials.
Number needed to treat (NNT)	The average number of patients who need to be treated to get a positive outcome. For example, if the NNT is 4, then 4 patients would have to be treated to ensure 1 of them gets better. The closer the NNT is to 1, the better the treatment.  For example, if you give a stroke prevention drug to 20 people before 1 stroke is prevented, the number needed to treat is 20. See also number needed to harm, absolute risk reduction.
Observational study	Individuals or groups are observed or certain factors are measured. No attempt is made to affect the outcome. For example, an observational study of a disease or treatment would allow 'nature' or usual medical care to take its course. Changes or differences in one characteristic (for example, whether or not people received a specific treatment or intervention) are studied without intervening.  There is a greater risk of selection bias than in experimental studies.
Odds ratio	Odds are a way to represent how likely it is that something will happen (the probability). An odds ratio compares the probability of something in one group with the probability of the same thing in another.  An odds ratio of 1 between 2 groups would show that the probability of the event (for example a person developing a disease, or a treatment working) is the same for both. An odds ratio greater than 1

Term	Definition
	<p>means the event is more likely in the first group. An odds ratio less than 1 means that the event is less likely in the first group.</p> <p>Sometimes probability can be compared across more than 2 groups – in this case, one of the groups is chosen as the 'reference category', and the odds ratio is calculated for each group compared with the reference category. For example, to compare the risk of dying from lung cancer for non-smokers, occasional smokers and regular smokers, non-smokers could be used as the reference category. Odds ratios would be worked out for occasional smokers compared with non-smokers and for regular smokers compared with non-smokers. See also confidence interval, risk ratio.</p>
Opportunity cost	The loss of other healthcare programmes displaced by investment in or introduction of another intervention. This may be best measured by the health benefits that could have been achieved had the money been spent on the next best alternative healthcare intervention.
Outcome	<p>The impact that a test, treatment, policy, programme or other intervention has on a person, group or population. Outcomes from interventions to improve the public's health could include changes in knowledge and behaviour related to health, societal changes (for example, a reduction in crime rates) and a change in people's health and wellbeing or health status. In clinical terms, outcomes could include the number of patients who fully recover from an illness or the number of hospital admissions, and an improvement or deterioration in someone's health, functional ability, symptoms or situation. Researchers should decide what outcomes to measure before a study begins.</p>
P value	<p>The p value is a statistical measure that indicates whether or not an effect is statistically significant.</p> <p>For example, if a study comparing 2 treatments found that one seems more effective than the other, the p value is the probability of obtaining these results by chance. By convention, if the p value is below 0.05 (that is, there is less than a 5% probability that the results occurred by chance) it is considered that there probably is a real difference between treatments. If the p value is 0.001 or less (less than a 1% probability that the results occurred by chance), the result is seen as highly significant.</p> <p>If the p value shows that there is likely to be a difference between treatments, the confidence interval describes how big the difference in effect might be.</p>
Perioperative	The period from admission through surgery until discharge, encompassing the preoperative and postoperative periods.
Placebo	A fake (or dummy) treatment given to participants in the control group of a clinical trial. It is indistinguishable from the actual treatment (which is given to participants in the experimental group). The aim is to determine what effect the experimental treatment has had – over and above any placebo effect caused because someone has received (or thinks they have received) care or attention.
Polypharmacy	The use or prescription of multiple medications.
Posterior distribution	In Bayesian statistics this is the probability distribution for a statistic based after combining established information or belief (the prior) with new evidence (the likelihood).
Positive predictive value (PPV)	In screening or diagnostic tests: A measure of the usefulness of a screening or diagnostic test. It is the proportion of those with a positive test result who have the disease, and can be interpreted as the probability that a positive test result is correct. It is calculated as follows: $TP/(TP+FP)$
Postoperative	Pertaining to the period after patients leave the operating theatre,

Term	Definition
	following surgery.
Post-test probability	In diagnostic tests: The proportion of patients with that particular test result who have the target disorder (post-test odds/[1 plus post-test odds]).
Power (statistical)	The ability to demonstrate an association when one exists. Power is related to sample size; the larger the sample size, the greater the power and the lower the risk that a possible association could be missed.
Preoperative	The period before surgery commences.
Pre-test probability	In diagnostic tests: The proportion of people with the target disorder in the population at risk at a specific time point or time interval. Prevalence may depend on how a disorder is diagnosed.
Prevalence	See Pre-test probability.
Prior distribution	In Bayesian statistics this is the probability distribution for a statistic based on previous evidence or belief.
Primary care	Healthcare delivered outside hospitals. It includes a range of services provided by GPs, nurses, health visitors, midwives and other healthcare professionals and allied health professionals such as dentists, pharmacists and opticians.
Primary outcome	The outcome of greatest importance, usually the one in a study that the power calculation is based on.
Probabilistic analysis	In economic evaluation, this is an analysis that uses a probability distribution for each input. In contrast, see Deterministic analysis.
Product licence	An authorisation from the MHRA to market a medicinal product.
Prognosis	A probable course or outcome of a disease. Prognostic factors are patient or disease characteristics that influence the course. Good prognosis is associated with low rate of undesirable outcomes; poor prognosis is associated with a high rate of undesirable outcomes.
Prospective study	A research study in which the health or other characteristic of participants is monitored (or 'followed up') for a period of time, with events recorded as they happen. This contrasts with retrospective studies.
Publication bias	Publication bias occurs when researchers publish the results of studies showing that a treatment works well and don't publish those showing it did not have any effect. If this happens, analysis of the published results will not give an accurate idea of how well the treatment works. This type of bias can be assessed by a funnel plot.
Quality of life	See 'Health-related quality of life'.
Quality-adjusted life year (QALY)	A measure of the state of health of a person or group in which the benefits, in terms of length of life, are adjusted to reflect the quality of life. One QALY is equal to 1 year of life in perfect health.  QALYS are calculated by estimating the years of life remaining for a patient following a particular treatment or intervention and weighting each year with a quality of life score (on a scale of 0 to 1). It is often measured in terms of the person's ability to perform the activities of daily life, freedom from pain and mental disturbance.
Randomisation	Assigning participants in a research study to different groups without taking any similarities or differences between them into account. For example, it could involve using a random numbers table or a computer-generated random sequence. It means that each individual (or each group in the case of cluster randomisation) has the same chance of receiving each intervention.
Randomised controlled trial (RCT)	A study in which a number of similar people are randomly assigned to 2 (or more) groups to test a specific drug or treatment. One group

Term	Definition
	(the experimental group) receives the treatment being tested, the other (the comparison or control group) receives an alternative treatment, a dummy treatment (placebo) or no treatment at all. The groups are followed up to see how effective the experimental treatment was. Outcomes are measured at specific times and any difference in response between the groups is assessed statistically. This method is also used to reduce bias.
RCT	See 'Randomised controlled trial'.
Receiver operating characteristic (ROC) curve	A graphical method of assessing the accuracy of a diagnostic test. Sensitivity is plotted against 1 minus specificity. A perfect test will have a positive, vertical linear slope starting at the origin. A good test will be somewhere close to this ideal.
Reference standard	The test that is considered to be the best available method to establish the presence or absence of the outcome – this may not be the one that is routinely used in practice.
Reporting bias	See 'Publication bias'.
Resource implication	The likely impact in terms of finance, workforce or other NHS resources.
Retrospective study	A research study that focuses on the past and present. The study examines past exposure to suspected risk factors for the disease or condition. Unlike prospective studies, it does not cover events that occur after the study group is selected.
Review question	In guideline development, this term refers to the questions about treatment and care that are formulated to guide the development of evidence-based recommendations.
Risk ratio/relative risk (RR)	<p>The ratio of the risk of disease or death among those exposed to certain conditions compared with the risk for those who are not exposed to the same conditions (for example, the risk of people who smoke getting lung cancer compared with the risk for people who do not smoke).</p> <p>If both groups face the same level of risk, the risk ratio is 1. If the first group had a risk ratio of 2, subjects in that group would be twice as likely to have the event happen. A risk ratio of less than 1 means the outcome is less likely in the first group. The risk ratio is sometimes referred to as relative risk.</p>
Secondary outcome	An outcome used to evaluate additional effects of the intervention deemed a priori as being less important than the primary outcomes.
Selection bias	<p>Selection bias occurs if:</p> <ul style="list-style-type: none"> <li>a) The characteristics of the people selected for a study differ from the wider population from which they have been drawn, or</li> <li>b) There are differences between groups of participants in a study in terms of how likely they are to get better.</li> </ul>
Sensitivity	<p>How well a test detects the thing it is testing for.</p> <p>If a diagnostic test for a disease has high sensitivity, it is likely to pick up all cases of the disease in people who have it (that is, give a 'true positive' result). But if a test is too sensitive it will sometimes also give a positive result in people who don't have the disease (that is, give a 'false positive').</p> <p>For example, if a test were developed to detect if a woman is 6 months pregnant, a very sensitive test would detect everyone who was 6 months pregnant, but would probably also include those who are 5 and 7 months pregnant.</p> <p>If the same test were more specific (sometimes referred to as having higher specificity), it would detect only those who are 6 months pregnant, and someone who was 5 months pregnant would get a negative result (a 'true negative'). But it would probably also miss</p>

Term	Definition
	<p>some people who were 6 months pregnant (that is, give a ‘false negative’).</p> <p>Breast screening is a ‘real-life’ example. The number of women who are recalled for a second breast screening test is relatively high because the test is very sensitive. If it were made more specific, people who don’t have the disease would be less likely to be called back for a second test but more women who have the disease would be missed.</p>
Sensitivity analysis	<p>A means of representing uncertainty in the results of economic evaluations. Uncertainty may arise from missing data, imprecise estimates or methodological controversy. Sensitivity analysis also allows for exploring the generalisability of results to other settings. The analysis is repeated using different assumptions to examine the effect on the results.</p> <p>One-way simple sensitivity analysis (univariate analysis): each parameter is varied individually in order to isolate the consequences of each parameter on the results of the study.</p> <p>Multi-way simple sensitivity analysis (scenario analysis): 2 or more parameters are varied at the same time and the overall effect on the results is evaluated.</p> <p>Threshold sensitivity analysis: the critical value of parameters above or below which the conclusions of the study will change are identified.</p> <p>Probabilistic sensitivity analysis: probability distributions are assigned to the uncertain parameters and are incorporated into evaluation models based on decision analytical techniques (for example, Monte Carlo simulation).</p>
Significance (statistical)	<p>A result is deemed statistically significant if the probability of the result occurring by chance is less than 1 in 20 (<math>p &lt; 0.05</math>).</p>
Specificity	<p>The proportion of true negatives that are correctly identified as such. For example in diagnostic testing the specificity is the proportion of non-cases correctly diagnosed as non-cases.</p> <p>See related term ‘Sensitivity’.</p> <p>In terms of literature searching a highly specific search is generally narrow and aimed at picking up the key papers in a field and avoiding a wide range of papers.</p>
Stakeholder	<p>An organisation with an interest in a topic that NICE is developing a guideline or piece of public health guidance on. Organisations that register as stakeholders can comment on the draft scope and the draft guidance. Stakeholders may be:</p> <ul style="list-style-type: none"> <li>• manufacturers of drugs or equipment</li> <li>• national patient and carer organisations</li> <li>• NHS organisations</li> <li>• organisations representing healthcare professionals.</li> </ul>
State transition model	<p>See Markov model</p>
Systematic review	<p>A review in which evidence from scientific studies has been identified, appraised and synthesised in a methodical way according to predetermined criteria. It may include a meta-analysis.</p>
Time horizon	<p>The time span over which costs and health outcomes are considered in a decision analysis or economic evaluation.</p>
Transition probability	<p>In a state transition model (Markov model), this is the probability of moving from one health state to another over a specific period of time.</p>
Treatment allocation	<p>Assigning a participant to a particular arm of a trial.</p>
Univariate	<p>Analysis which separately explores each variable in a data set.</p>

Term	Definition
Utility	In health economics, a 'utility' is the measure of the preference or value that an individual or society places upon a particular health state. It is generally a number between 0 (representing death) and 1 (perfect health). The most widely used measure of benefit in cost–utility analysis is the quality-adjusted life year, but other measures include disability-adjusted life years (DALYs) and healthy year equivalents (HYEs).

1  
2

# 5 Appendix 1

## Round One

Profession/Role	
Person affected by the condition	23.9%
Dietician	0.9%
Colorectal surgeon	47.0%
GP	6.8%
Gastroenterologist	10.3%
Pharmacist	0.9%
Radiologist	2.6%
Other	7.7%

Work setting	
Primary	21.3%
Secondary	72.3%
Other	6.4%

Area of country	
East Midlands	20.5%
East of England	5.1%
Greater London	6.0%
North East England	4.3%
North West England	6.8%
Northern Ireland	3.4%
Scotland	6.8%
South East England	11.1%
South West England	5.1%
Wales	7.7%
West Midlands	9.4%
Yorkshire and the Humber	7.7%
Other	6.0%

Signs and symptoms of suspected diverticular disease		
<b>Suspect diverticular disease if a person presents with:</b>		

<ul style="list-style-type: none"> <li>Intermittent abdominal pain in the left lower quadrant. Pain may be triggered by eating and may be relieved by the passage of stool or flatus.</li> </ul> <p>Note: in a minority of people and in people of Asian origin, pain may be localized in the right lower quadrant.</p>	72% (strongly agree or agree)	Consensus
<ul style="list-style-type: none"> <li>Constipation, diarrhoea, or occasional large rectal bleeds.</li> </ul>	74%	Consensus
<ul style="list-style-type: none"> <li>Bloating and the passage of mucus rectally.</li> </ul>	60%	Common responses: Bloating non-specific n=11 Bloating indicates IBS/IBD n=8 Not seen mucus n=5 ACTION: Remove
<ul style="list-style-type: none"> <li>Tenderness in the left lower quadrant on abdominal examination</li> </ul>	79%	Consensus
<p>If a person has suspected diverticular disease, but the diagnosis has not been confirmed, arrange routine investigations or a routine referral to a specialist or to confirm the diagnosis.</p>	67%	Common responses: Would not refer n=4 could refer to open investigations (colonoscopy, sigmoid, CT) n=4 Need to exclude cancer/other diagnosis n=8 ACTION: Add to recommendation The guideline will cross refer to the NICE guideline on Suspected cancer: recognition and referral (NG12).

1

<b>Signs and symptoms of suspected acute diverticulitis</b>		
<b>Suspect acute diverticulitis:</b>		
<ul style="list-style-type: none"> <li>Constant abdominal pain, usually severe and starting in the hypogastrium before localizing in the left lower quadrant, with fever.</li> </ul> <p>Note: in a minority of people and in people of Asian origin, pain may be localized in the right lower quadrant.</p>	73%	Consensus
<ul style="list-style-type: none"> <li>Change in bowel habit, and possible significant rectal bleeding or passage of mucus per rectum.</li> </ul>	63%	Common responses: Exclude cancer/other diagnosis n=9 Non-specific n=2 Bleeding not common n=6 ACTION: The guideline will cross refer to the NICE guideline on Suspected cancer: recognition and referral

		(NG12).
<ul style="list-style-type: none"> <li>• Possible nausea, vomiting, dysuria, and urinary frequency</li> </ul>	58%	Common responses: unusual presentation/ non specific n=9 Indicate urinary tract infection N=4 ACTION: Remove
<ul style="list-style-type: none"> <li>• A previous history of diverticulosis or diverticulitis</li> </ul>	85%	Consensus
<ul style="list-style-type: none"> <li>• Tenderness in the left lower quadrant, palpable abdominal mass or distention on abdominal examination.</li> </ul>	76%	Consensus

1

<b>Signs and symptoms of complicated diverticulitis</b>		
<b>Suspect a complication of diverticulitis if the person is systemically unwell and presents with possible:</b>		
<ul style="list-style-type: none"> <li>• Intra-abdominal abscess formation — suggested by an abdominal mass on examination or peri-rectal fullness on internal rectal examination (for example due to a low-lying pelvic abscess).</li> </ul>	87%	Consensus
<ul style="list-style-type: none"> <li>• Perforation and peritonitis — suggested by abdominal rigidity, guarding, and rebound tenderness on examination.</li> </ul>	94%	Consensus
<ul style="list-style-type: none"> <li>• Sepsis — suggested by skin discolouration, raised or lowered temperature, rigors, change in conscious level or confusion, rapid pulse, and reduced urination.</li> </ul>	82%	Consensus
<ul style="list-style-type: none"> <li>• Stricture and fistula formation — the presence of faecaluria, pneumaturia, or pyuria may suggest colovesical fistula.</li> </ul>	95%	Consensus
<ul style="list-style-type: none"> <li>• Intestinal obstruction — suggested by colicky abdominal pain, constipation, vomiting, inability to pass flatus, and abdominal distention.</li> </ul>	90%	Consensus

2

<b>The management of diverticulosis</b>		
Encourage people to drink an adequate fluid intake with a high-fibre diet, especially if there is a risk of dehydration.	66%	Common responses: No changes suggested

<b>The management of diverticulosis</b>		
Encourage people to drink adequate fluid if increasing fibre intake, especially if there is a risk of dehydration.		ACTION: Move recommendation to appear as a bullet point below the statement beginning 'Encourage people to eat a healthy, balanced diet and regular meals'. To be incorporated in round 2 of Delphi survey.
<b>Encourage people to eat a healthy, balanced diet and regular meals:</b>		
<ul style="list-style-type: none"> <li>the diet should contain whole grains, fruit and vegetables</li> </ul>	81%	Consensus
<ul style="list-style-type: none"> <li>reduce red meat intake.</li> </ul>	66%	Common responses: No evidence n=14  ACTION: Remove
<ul style="list-style-type: none"> <li>Fibre intake should be increased gradually (to minimise flatulence and bloating) — adults should aim to consume 30 g of fibre per day to reduce the risk of developing symptomatic diverticular disease. If you symptom is constipation...</li> </ul>	64%	Common responses: No evidence for this n=9 Can't have fibre at all/ no issue with fibre n=6  ACTION: Add 'If constipation is present' to statement
<ul style="list-style-type: none"> <li>Be aware that there is no need to avoid seeds, nuts and fruit skins</li> </ul>	71%	Consensus
Advise the person that the beneficial effects of increasing dietary fibre may take several weeks.	68%	No responses Remove as reference to increasing fibre is only for people with constipation
Advise that a high-fibre diet should be maintained for life.	70%	No responses Remove as reference to increasing fibre is only for people with constipation
Consider bulk-forming laxatives to avoid constipation	78%	Consensus
Advise the person of the beneficial effects of:		
<ul style="list-style-type: none"> <li>Weight loss if the person is overweight or obese</li> </ul>	77%	Consensus
<ul style="list-style-type: none"> <li>Exercise</li> </ul>	76%	Consensus
Routine follow-up is not necessary if there is no progression to symptomatic diverticular disease or diverticulitis.	92%	Consensus

1

#### **The management of confirmed diverticular disease**

<b>Encourage people to eat a healthy, balanced diet and regular meals:</b>		
<ul style="list-style-type: none"> <li>the diet should contain whole grains, fruit and vegetables</li> </ul>	84%	Consensus
<ul style="list-style-type: none"> <li>reduce red meat intake.</li> </ul>	65%	Common responses: No evidence n=15  ACTION: Remove
<ul style="list-style-type: none"> <li>Fibre intake should be increased gradually (to minimize flatulence and bloating) — adults should aim to consume 30 g of fibre per day to reduce the risk of developing symptomatic diverticular disease. If constipation</li> </ul>	68%	Common responses: No evidence n=8 Fibre doesn't help/makes things worse n=6  ACTION: Add 'If constipation is present' to the statement
<ul style="list-style-type: none"> <li>Be aware that there is no need to avoid seeds, nuts and fruit skins</li> </ul>	78%	Consensus
<ul style="list-style-type: none"> <li>Advise the person that the beneficial effects of increasing dietary fibre may take several weeks.</li> </ul>	72%	Consensus
<ul style="list-style-type: none"> <li>Advise that a high-fibre diet should be maintained for life.</li> </ul>	75%	Consensus
Encourage people to drink an adequate fluid intake with a high-fibre diet, especially if there is a risk of dehydration.	86%	Consensus
Consider bulk-forming laxatives if a high-fibre diet is unacceptable or not possible or if symptoms of constipation or diarrhoea persist	83%	Consensus
Consider analgesia for example paracetamol as-needed, if the person has ongoing abdominal pain.	84%	Consensus
Advise that nonsteroidal anti-inflammatory drugs (NSAIDs) and opioid analgesia (for example codeine) should be avoided if possible, due to the potential to increase risk of diverticular perforation.	80%	Consensus
Consider an antispasmodic for abdominal cramping (Note: examples of antispasmodics include buscopan and peppermint oil)	90%	Consensus
Consider using prebiotics and probiotics for abdominal pain.	61%	Common responses: No clear evidence n=16  ACTION: Remove

Do not use antibiotics	63%	Common responses:  Not required N=7 If infection N=9  ACTION: Add 'In the absence of acute diverticulitis'
Advise the person of the beneficial effects of: <ul style="list-style-type: none"> <li>• Weight loss if the person is overweight or obese</li> <li>• Exercise</li> </ul>	84% 84%	Consensus Consensus
If there are persistent or refractory symptoms, consider alternative causes for symptoms, and manage appropriately.	99%	Consensus

1  
2  
3

### Round two

<b>Profession/Role</b>	
Person affected by the condition	13%
Colorectal surgeon	63.8%
GP	7.2%
Gastroenterologist	8.7%
Radiologist	4.3%
Other	2.9%

4

<b>Work setting</b>	
Primary	8.7%
Secondary	78.3%
Not relevant	11.6%
Other	1.4%

5

<b>Area of country</b>	
East Midlands	15.9%
East of England	8.7%
Greater London	4.3%
North East England	2.9%
North West England	15.9%
Northern Ireland	4.3%
Scotland	5.8%
South East England	5.8%
South West England	8.7%
Wales	4.3%
West Midlands	11.6%

Yorkshire and the Humber	5.8%
Other	5.8%

1

Signs and symptoms of suspected diverticular disease		
<p>If a person has suspected diverticular disease, but the diagnosis has not been confirmed, arrange routine investigations or a routine referral to a specialist confirm the diagnosis.</p> <p>Please note we will cross refer to the NICE guideline on 'Suspected cancer: Recognition and referral' (NG12)</p>	Strongly agree or agree 88%	Consensus

2

Signs and symptoms of suspected acute diverticulitis		
<p>Please note we cross refer to the NICE guideline on 'Suspected cancer: Recognition and referral' (NG12)</p> <p>Suspect acute diverticulitis:</p> <ul style="list-style-type: none"> <li>Constant abdominal pain, usually severe and starting in the hypogastrium before localizing in the left lower quadrant, with fever. (This has reached consensus)</li> </ul>	Consensus in round 1	The statement was present to provide context for the statement that had not. People commented that hypogastrium is an outdated word Remove "starts in hypogastrium"
<p>(Note: in a minority of people and in people of Asian origin, pain may be localized in the right lower quadrant).</p> <ul style="list-style-type: none"> <li>Change in bowel habit, and possible significant rectal bleeding or passage of mucus per rectum.</li> </ul>	64%	<p>Common responses: Associated with malignancy = 8 Not associated with acute diverticulitis = 4</p> <p>ACTION: Remove</p>

3

The management of diverticulosis		
<ul style="list-style-type: none"> <li>If constipation is present fibre intake should be increased gradually (to minimise flatulence and bloating) — adults should aim to consume 30 g of fibre per day to reduce the risk of developing symptomatic diverticular disease.</li> </ul>	70%	<p>Consensus</p> <p>The GC removed reference to 30 g of fibre as it was noted that people do not know what 30 g represents</p>
<ul style="list-style-type: none"> <li>Encourage people to drink adequate fluid if increasing fibre intake, especially if there is a risk of dehydration</li> </ul>	87%	Consensus

1

<b>Management of confirmed diverticular disease</b>		
In the absence of acute diverticulitis do not use antibiotics	97%	Consensus

2

3

## References

1. Goodman C. A Delphi Survey of clinical nursing research priorities within a regional health authority. London. University of London. 1986. [unpublished]
2. Gordon TJ. Current methods of future research. Middletown, Connecticut. Institute for the Future, 1971.
3. GRADE Working Group. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) Working Group website. 2011. Available from: <http://www.gradeworkinggroup.org/> Last accessed: 15/01/2019
4. National Institute for Health and Care Excellence. Developing NICE guidelines: the manual. London. National Institute for Health and Care Excellence, 2014. Available from: <http://www.nice.org.uk/article/PMG20/chapter/1%20Introduction%20and%20overview>
5. National Institute for Health and Clinical Excellence. Social value judgements: principles for the development of NICE guidance. London. National Institute for Health and Clinical Excellence, 2008. Available from: <https://www.nice.org.uk/media/default/about/what-we-do/research-and-development/social-value-judgements-principles-for-the-development-of-nice-guidance.pdf>
6. National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal 2013. London. National Institute for Health and Clinical Excellence, 2013. Available from: <http://publications.nice.org.uk/pmg9>
7. Organisation for Economic Co-operation and Development (OECD). Purchasing power parities (PPP). 2012. Available from: <http://www.oecd.org/sdd/prices-ppp/> Last accessed: 02/02/18
8. Review Manager (RevMan) [Computer program]. Version 5. Copenhagen. The Nordic Cochrane Centre, The Cochrane Collaboration, 2015. Available from: <http://tech.cochrane.org/Revman>
9. Strauss H, Zeigler H. The delphi technique and its uses in social science research. *The Journal of Creative Behavior*. 1975; 9(4):253-259